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Historically, natural products have served as valuable sources of drugs to treat many 
human diseases.[1]  Examples include the antimalarial drugs quinine from the cinchona 
tree[2] and artemisinin from the sweet wormwood,[3] the antiparasitic drug ivermectin, a 
derivative of the natural product avermectin from the bacterium Streptomyces 
avermitilis,[4] and the antibiotic vancomycin from the soil bacterium Amycolatopsis 
orientalis.[5] Although many natural products are derived from terrestrial sources, the 
marine environment has the potential to provide a vast array of novel drug molecules.[6]  
Approximately 35,000 natural products from marine sources have been chemically 
characterized, including seven FDA-approved marine-derived drugs for cancer, viral 
diseases, chronic pain, and reducing triglyceride levels in blood.[7,8] These discoveries 
represent only a fraction of the natural products present in the marine environment since 
more than 70% of Earth’s surface is covered by relatively unexplored ocean habitats.[9] 
Additionally, advances in technology and improvements in culturing and isolation 
techniques have fueled studies of underexplored marine natural products produced by 
marine microbes.[10,11] Marine organisms are exposed to a wide variety of pathogenic 
microbes and are subject to selection pressures as a result of predation, disease, herbivory, 
and competition for limited resources in their native environments, resulting in the 
evolution of a vast array of unique secondary metabolites.[12,13] In addition, due to the high 
abundance of halides in the marine environment, many marine organisms incorporate 
chlorine, bromine, and iodine into secondary metabolites, which are not as common in 
terrestrial natural products and confer additional functionality.[12]  
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One area of marine natural products research that has shown great promise is the 
application of these compounds as treatments for infectious diseases such as malaria and 
hookworm infection.[14] In fact, there is a dire need to identify new treatment options for 
infection by the malarial parasite Plasmodium which has evolved resistance to currently 
available antimalarial drugs.[15-17] Additionally, two species of Plasmodium, P. vivax and 
P. ovale, can develop into hypnozoites, a dormant form of the parasite’s life cycle located 
in the host’s liver that do not cause symptoms and can trigger a new occurrence of malaria 
months to years after initial infection.[18,19] Chapter 1 details the characterization of five 
natural products isolated from a cyanobacterium Moorea producens that exhibit promising 
activity against both blood and liver-stages of malaria. Soil-transmitted helminths, such as 
hookworms, can negatively impact human physical and cognitive development, impair 
productivity, and be generally debilitating.[20,21] According to a survey of neglected 
tropical disease experts, there is consensus that current drugs, vaccines, and vector controls 
are not adequate for the elimination of soil-transmitted helminth infections.[22] Efforts to 
eradicate infectious worms are hindered by the evolution of resistance to currently 
available drugs, limited treatment options, and a high frequency of reinfection. Chapter 3 
presents separation and structural characterization of natural products from a mixed 
cyanobacterial collection that exhibited activity against infectious hookworms.  
Since marine organisms do not encounter the same pathogens as humans in their 
own habitats, a relevant question to ask is what roles newly discovered marine natural 
products play in natural environments. Previous studies have shown that bioactive 
molecules can act as defense molecules against ecologically relevant pathogens,[23] as 
allelopathic agents against competitors,[24] as antifouling chemicals that prevent 
 xvii 
attachment of biofoulers on organismal surfaces,[25] or as feeding deterrents against 
predators, among many other roles.[26] In chapter 2, the natural product peyssonnoside A, 
isolated from a red alga Peyssonnelia sp., was found to suppress growth of a marine fungus, 
indicating that peyssonnoside A exhibits an antifungal ecological role.  
An important aspect of the drug discovery process is evaluation of the mechanism 
of action (MOA) of bioactive molecules.[27] Numerous methods exist for probing small 
molecule MOA including microscopy, biochemical techniques (e.g., affinity-based 
purification, gene expression-based profiling), molecular modeling and docking, and 
omics-based approaches (e.g., metabolomics, proteomics, transcriptomics, 
genomics).[28,29] Chapter 1 includes computational predictions used to generate 
hypotheses about protein-ligand binding as a means of evaluating possible MOAs for 
antimalarial cyanobacterial natural products isolated in minute quantities. Applying 
computational modeling as a step in evaluating possible MOAs is valuable since it allows 
for prioritization of laboratory experiments for confirming predictions while minimizing 
the consumption of precious natural products. A metabolomics approach is presented in 
chapter 4 for evaluating the MOA of a natural product isolated from the green alga 
Cladophora socialis against methicillin-resistant Staphylococcus aureus. Metabolomics 
allows for the systematic comparison of complex mixtures of small molecules present in 
different biological systems, for example, comparing the metabolomes of a pathogen under 
different treatment conditions enables detection of metabolic pathways altered upon 
exposure to a candidate drug.[30] Of the omics-based techniques, metabolomics provides 
the closest representation of cellular phenotype as it probes differences in metabolites that 
reflect the underlying biochemical pathways.[31,32]   
 xviii 
In summary, this dissertation provides a comprehensive view of the many 
milestones involved in the natural product drug discovery process, from collection of 
marine organisms in the field to isolation and structural elucidation of bioactive natural 
products, and exploration of their biological functions. Important insights were gained by 
probing the ecological role of a natural product in its natural environment and evaluating 





CHAPTER 1.      ANTIMALARIAL PEPTIDE AND POLYKETIDE 
NATURAL PRODUCTS FROM THE FIJIAN MARINE 




 This section is adapted from the paper A.M. Sweeney-Jones, K. Gagaring, J. 
Antonova-Koch, H. Zhou, N. Mojib, K. Soapi, J. Skolnick, C.W. McNamara, and J. 
Kubanek, Marine Drugs, 2020, 18(3), 167; https://doi.org/10.3390/md18030167. The 
copyright for this open access MDPI journal is retained by the authors.  
1.1 Abstract 
 A new cyclic peptide, kakeromamide B (1), and previously described cytotoxic 
cyanobacterial natural products ulongamide A (2), lyngbyabellin A (3), 18E-lyngbyaloside 
C (4), and lyngbyaloside (5) were identified from an antimalarial extract of the Fijian 
marine cyanobacterium Moorea producens. Compounds 1 and 2 exhibited promising 
activity against Plasmodium falciparum blood-stages with EC50 values of 0.89 and 0.99 
µM, respectively, whereas 3 was very potent with an EC50 value of 0.15 nM. Compounds 
1, 4, and 5 displayed liver-stage antimalarial activity against P. berghei liver schizonts with 
EC50 values of 1.1, 0.71, and 0.45 µM, respectively. The threading-based computational 
method FINDSITEcomb2.0 predicted the binding of 1 and 2 to potentially druggable proteins 
of Plasmodium falciparum, prompting formulation of hypotheses about possible 
mechanisms of action. Kakeromamide B (1) was predicted to bind to several Plasmodium 
actin-like proteins and a sortilin protein suggesting possible interference with parasite 
invasion of host cells. When 1 was tested in a mammalian actin polymerization assay, it 
stimulated actin polymerization in a dose-dependent manner, suggesting that 1 does, in 





Current malaria drugs are inadequate for future control of the disease due to the 
evolution of resistance by the malaria parasite, necessitating the discovery of medicines 
with novel mechanisms of action (MOA).[33,34] Additionally, pharmaceutical options 
remain limited for the liver-stage of malaria infection. Natural products such as artemisinin 
discovered by Nobel-prize winner Tu Youyou have served as valuable sources of drugs to 
treat malaria. [3,9] Promising nanomolar antimalarial activity has been reported for a wide 
range of marine-derived natural products including the polycyclic aromatic polyketide 
trioxacarcin A from a marine Streptomyces sp.,[35] the polyketide-derived cyanobacterial 
polyhydroxy macrolide bastimolide A,[36] and the β-carboline alkaloid manzamine A 
produced by a bacterial sponge symbiont.[37] Two sponge-derived antimalarial terpene 
isonitriles, diisocyanoadociane and axisonitrile-3, were predicted based on molecular 
dynamics simulations to interfere with heme detoxification, the same MOA as 
chloroquine.[38] Evolution of an efflux pump that prevents drug accumulation in the 
parasite’s food vacuole has resulted in resistance of Plasmodium to chloroquine,[39] 
illustrating the need for discovery of natural products with unique molecular targets to 
support future disease management. 
Marine cyanobacteria produce a wide variety of secondary metabolites, including 
peptides, polyketides, alkaloids, lipids, glycosidic macrolides, and terpenes,[40] with 
diverse bioactivities such as antibacterial, antifungal, anticancer, immunosuppressive, and 
anti-inflammatory.[41] Although the chemical space of this phylum has been extensively 
studied with over 800 natural products reported in the MarinLit™ database, treatments for 
parasitic infections have been relatively understudied, leading to opportunities to leverage 
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the diverse chemistry of marine cyanobacteria for pharmacological exploration. The 
pursuit of antiparasitic natural products has led to promising discoveries, such as the 
antimalarial cyanobacterial peptides carmabin A,[42] gallinamide A,[43] and venturamide 
A.[44] Exploration of new chemical entities and novel bioactivities of known compounds 
constitute promising routes for inspiring the development of new drug molecules. 
An extract of the marine cyanobacterium Moorea producens collected off the 
Northern Lau Islands of Fiji exhibited strong potency against the human malarial parasite 
Plasmodium falciparum and low toxicity to human liver cells. The goal of the present study 
was to characterize the natural products responsible for the observed antimalarial effects 
and to explore the intersection of blood-stage and liver-stage activities. These molecules 
were evaluated for possible protein binding targets using computational predictions 
generated by the program FINDSITEcomb2.0,[45,46] a threading-based, virtual ligand-
screening method that takes advantage of binding site conservation for evolutionarily 
distant proteins, and one of the putative molecular targets was confirmed via in vitro 
testing. 
1.3 Results and Discussion 
1.3.1 Molecular Structures of Natural Products from Moorea producens 
A Fijian collection of cyanobacteria identified by 16S rRNA sequencing as Moorea 
producens (Figure 1) was freeze-dried, extracted, and the resulting extract was subjected 
to vacuum liquid chromatography. Bioassay-guided fractionation using both blood-stage 
Plasmodium falciparum and liver-stage Plasmodium berghei pointed to four adjacent 
fractions that demonstrated potent blood and liver-stage antimalarial activity. Subsequent 
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purification of compounds from these fractions using solid-phase extraction (SPE) and 
high-performance liquid chromatography (HPLC) led to the isolation of 1–5 (Figure 2).  
 
 
Figure 1. Evolutionary relationship of Moorea producens G-0362 with closely 
related cyanobacterial species from the Family Oscillatoriaceae inferred by the 16S rRNA 
sequences using the Maximum Likelihood method based on the Kimura 2-parameter model 
in MEGA X. The percentage of replicate trees in which the associated species clustered 
together in the bootstrap test (1000 iterations) is shown next to the branches. The accession 
numbers of the 16S rRNA of respective cyanobacteria are mentioned in parentheses. The 
outgroup taxon is Gloeobacter violaceus. The 16S rRNA sequence from Moorea 
producens used in this study is underlined. The tree is drawn to scale, with branch lengths 





Figure 2. Natural products from the Fijian marine cyanobacterium Moorea 
producens, including the novel cyclic peptide kakeromamide B (1) [47-50].  
 
High-resolution electrospray ionization mass spectrometry (HRESIMS) was used 
to assign the molecular formula of 1 as C42H58N6O7S with 17 degrees of unsaturation from 
the pseudomolecular ions [M + H]+ at m/z 791.4150 and [M + Na]+ at m/z 813.3958. This 
matched the molecular formula of the known natural product kakeromamide A (6) (Figure 
2A),[51] but differences in nuclear magnetic resonance (NMR) chemical shifts indicated 
unique bond connectivities. The 1H NMR spectral data (Table 1) suggested a peptide based 
on the presence of three amide protons (δH 6.32, 8.61, and 8.71), two N-methyl singlets (δH 
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2.87 and 3.02), and four α-protons (δH 4.30, 5.23, 5.45, and 5.63), nearly identical to 6. In 
6, two methyl doublets at δH 0.78 and 0.94 corresponded to valine, missing in 1, while the 
1H NMR spectrum of 1 had a methyl doublet at δH 1.40 absent in 6. 2D NMR spectroscopic 
analysis using COSY, HSQC, and HMBC experiments identified these differing subunits 
as an alanine-derived thiazole carboxylic acid and a 3-amino-2-methyloctanoic acid 
(Amoa), distinct from the valine-derived thiazole carboxylic acid and 3-amino-2-
methylhexanoic acid (Amha) in 6. 2D NMR spectroscopy also confirmed the presence of 
valine and two N,O-dimethyl-tyrosines. The linear peptide sequence was established based 
on HMBC correlations between α-protons, N-methyls, or NHs and carbonyl carbons 
(Figure 3B; Table 1: H-2/C-1, H-39/C-1 and C-7, H-40/C-6 and C-16, NH-28/C-15, H-
28/C-27, H-26/C-25 and C-27, NH-32/C-24, and NH-2/C-30). The relative and absolute 
configurational assignments in 1 are proposed based on the similarity of chemical shifts 
and J couplings to 6, which was subjected to a modified Marfey’s method to establish 
absolute configuration.[51] In the current work, acid hydrolysis towards Marfey’s analysis 
was attempted, but yields were inadequate for confirming absolute configuration, given 







Figure 3. (A) Comparison of the known cyclic peptide kakeromamide A (6) [51] to 
the newly identified analog, kakeromamide B (1), with distinguishing moieties highlighted 
green. (B) Observed COSY (blue bonds) and HMBC (red arrows) correlations for 
kakeromamide B (1). 
 
Table 1. 1H (700 MHz) and 13C (175 MHz) NMR spectroscopic data of 
kakeromamide B (1) in CD3CN. 
no. 
δC (mult., J 
in Hz) 
δH (mult., J in Hz) COSY HMBC 
1 176.3    
2 56.9 4.30 t (7.1) H-3,2-NH C-1w,C-3,C-4w 
2-NH  6.32 d (6.6) H-2 C-30w 
3 30.8 1.80 m H-2,H-4,H-5  
4 18.6 0.78 d (6.9) H-3 C-2,C-3,C-5 
5 19.0 0.80 d (6.8) H-3 C-2,C-3,C-4 
6 172.1    
7 50.3 5.63 dd (4.9, 10.9) H-8a,H-8b  




Table 1 (continued) 
 
8b  2.74 dd (11.0, 16.1) H-7,H-8a C-7,C-9 
9 129.8    
10/14 130.0 6.89 d (8.5) H-11/13 C-8w,C-12 
11/13 114.7 6.78 d (8.7) H-10/14 C-9 
12 159.1    
15 168.9    
16 62.9 5.23 dd (5.0, 10.0) H-17a,H-17b  
17a 34.8 2.67 dd (10.1, 14.4) H-16,H-17b C-16 
17b  2.92 dd (4.9, 14.4) H-16,H-17a C-18 
18 130.7    
19/23 131.4 7.00 d (8.6) H-20/22 C-17,C-21 
20/22 114.9 6.60 d (8.7) H-19/23 C-18 
21 159.4    
24 169.5    
25 150.2    
26 123.2 8.02 s  C-25w,C-27 
27 171.6    
28 48.1 5.45 p (7.4) 28-NH,H-29 C-27w 
28-NH  8.61 d (7.8) H-28 C-15w 
29 24.0 1.40 d (6.9) H-28 C-27,C-28 
30 173.6    
31 44.5 2.63 qd (3.7, 6.8) H-32,H-38  




32-NH  8.71 d (10.2) H-32 C-24w 
33a 41.8 1.13 m H-32,H-33b,H-34a,b C-35w 
33b  1.72 m H-32,H-33a,H-34a,b  
34a 30.4 1.29 m H-33a,b C-36w 
34b  1.45 m H-33a,b  
35 33.7 1.35 m  C-37w 
36 24.5 1.35 m H-37  
37 14.9 0.88 t (6.6) H-36 
C-34,C-35,C-
36 
38 19.6 1.09 d (6.9) H-31 
C-30,C-31,C-
32 
39 31.4 3.02 s  C-1,C-7 
40 28.7 2.87 s  C-6,C-16 
41 56.0 3.74 s  C-12 
42 55.7 3.49 s  C-21 
 
wIndicates weak correlation. 
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Compounds 2–5 were identified by comparison of HRESIMS, 1H NMR, and COSY 
spectral data to the literature [47-50] (data provided in Appendix A). Total syntheses have 
been reported for 2–4, confirming the structures of 2 [52] and 3 [53] while leading to the 
structural revision of three stereogenic centers (C-10, 11, and 13) of 4.[54] Two natural 
products that appeared to belong to the lyngbyabellin class of natural products, referred to 
as lyngbyabellin-like 1 (LYN1) and 2 (LYN2), were isolated in very low yields (2.2 and 
2.8 µg, respectively) which hindered full structure elucidation. Similarities to known 
lyngbyabellins included the presence of two chlorines as determined from MS isotopic 
patterns, two downfield proton singlets (LYN1: δH 8.12, 8.16; LYN2: δH 8.11, 8.27) 
suggestive of thiazole moieties, and methyl singlets with chemical shifts matching the 
methyl adjacent to the dichloromethylene in 3 (LYN1: δH 2.04; LYN2: δH 2.07). Since 
these natural products exhibited promising blood-stage antimalarial activity (Table 2), 
HRESIMS and 1H NMR spectral data are included in the appendix section even though 
complete structures were not determined. 
 
 











1 0.89 1.1d, > 1.2e >2.3 >2.3 
2 0.99 >4.0c >4.8 not tested 
3 0.00015 >1.0d,e 1.9 0.33 
4 > 1.9 0.71d, > 1.6e >3.1 1.7 
5 > 0.79 0.45d, > 0.63e >1.3 >1.3 
lyngbyabellin-like 1 (LYN1) 0.0073 >0.32e,d >0.65 0.45 
lyngbyabellin-like 2 (LYN2) 0.11 >0.26e,d >0.52 >0.52 
Atovaquone (+ control) 0.0061 < 0.00028c, 
0.0017d, 
0.0037e 
>2.0 not tested 
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Table 2 (continued) 
aHalf-maximal effective concentration (EC50) (μM). 
bHalf-maximal cytotoxicity 
concentration (μM). cNatural product tested against P. berghei sporozoites sourced from 
New York University (NYU) School of Medicine. Later liver-stage P. berghei testing used 
sporozoites from the University of Georgia (UGA)d and University of California San Diego 
(UCSD)e. 
 
1.3.2 Biological Activities of Cyanobacterial Natural Products 
The antimalarial activities of 1–5 were evaluated against asexual blood-stage 
Plasmodium falciparum and liver-stage P. berghei assays while cytotoxicity was measured 
with HEK293T and HepG2 human cell lines (Table 2). Lyngbyabellin A (3) exhibited 
remarkable activity against blood-stage P. falciparum with a half-maximal effective 
concentration (EC50) value of 0.15 nM. Additionally, 3 exhibited a high selectivity index 
of 13,000 and 2,200 for Plasmodium versus normal kidney epithelial cells (HEK293T) and 
human liver carcinoma cells (HepG2), respectively. Lynbyabellin A (3) was more potent 
than atovaquone (Table 2), indicating that it could be a promising antimalarial drug 
candidate, especially since a route to production via total synthesis exists.[53] 
Lyngbyabellins LYN1 and LYN2 also exhibited promising activity against blood-stage P. 
falciparum with EC50 values of 0.0073 and 0.11 μM, respectively. To date, 18 
lyngbyabellins have been reported, all structurally related to dolabellin [55] with two 
disubstituted thiazole rings and a dichloro substituted aliphatic chain.[48,49,56-61] 
Lyngbyabellins possess varying degrees of cytotoxicity against cancer cell lines but had 
not previously been evaluated for antimalarial properties. Due to the promising antimalarial 
activities reported in the current study (Table 2), future experiments could evaluate 
antimalarial mechanisms of action and structure-activity relationships of lyngbyabellins. 
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Although less potent, cyclic depsipeptide 2 and cyclic peptide 1 still exhibited 
promising blood-stage antimalarial activity with a EC50 values of 0.99 and 0.89 µM, 
respectively, whereas 4 and 5 were inactive (Table 2). Evaluation of liver-stage 
antimalarial activity indicated that 1, 4, and 5 are inhibitory against P. berghei liver 
schizont development (sourced from UGA) with EC50 values of 1.1, 0.71, and 0.45 µM, 
respectively. These same natural products were less active against P. berghei sourced from 
UCSD. None of these natural products exhibited cytotoxicity against HEK293T or HepG2 
human cell lines. Characteristics of the ideal drug candidate for treating malaria include 
safety, especially for vulnerable populations such as children under the age of five, and 
targeting more than one Plasmodium life stage.[62] Although 1 did not exhibit the most 
potent antimalarial activity of the cyanobacterial natural products evaluated, its ability to 
inhibit both the blood and liver life stages of Plasmodium coupled with its low cytotoxicity 
towards human cell lines make it a promising lead for drug discovery. 
1.3.3 Putative Molecular Targets of Cyanobacterial Natural Products 
Modeling of protein-ligand interactions with the FINDSITEcomb2.0 [46] prediction 
algorithm suggested that numerous Plasmodium proteins are likely to interact directly with 
these cyanobacterial natural products. Several malarial protein classes were predicted to 
bind to kakeromamide B (1) including actin-like proteins, sortilin, and glutamyl-
tRNA(Gln) amidotransferase subunit A. Ranking of protein-ligand interactions by mTC, a 
composite Tanimoto Coefficient based on fingerprint for ligand similarity measurement, 
and precision values indicated that actins had the highest probability of binding 1 (Table 
3). One of the Plasmodium actins predicted to bind with 1, actin-1, has been found to be 
involved with host cell invasion.[63] Since the malarial parasite life cycle requires entry 
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into human erythrocytes, inhibiting the ability of Plasmodium to invade host cells could be 
a viable mechanism of action. The malarial protein with the next highest mTC and 
precision values for binding 1, sortilin, is important for the formation of apical complex 
components and creation of merozoites.[64] In parasite strains where the expression of 
sortilin is suppressed, new merozoites, which are the invasive form of the parasite, cannot 
be formed. Thus, like actin, inhibition of sortilin could impact Plasmodium’s ability to 
infect host cells suggesting that this protein could also be a feasible target for future 
exploration. Glutamyl-tRNA(Gln) amidotransferase subunit A is essential for the parasite’s 
blood-stage.[65] This protein is required for the synthesis of glutamyl-tRNA-gln, a protein 
synthesis building block needed for parasite propagation.[66] Since the precision value for 
glutamyl-tRNA(Gln) amidotransferase subunit A was relatively low, this target is less 
promising.  
 
Table 3. Proteins predicted to bind to kakeromamide B (1) using the protein-ligand 
prediction algorithm FINDSITEcomb2.0.[46] Higher values for mTC (a Tanimoto Coefficient 
based fingerprint for similarity measure) and precision correspond to higher probability of 
the protein being a true target. 
Accession Number Protein Description mTC  Precision 
Q8ILW9 Actin-2 0.50 0.77 
Q8ILM5 Actin-related protein homolog, arp4 0.50 0.77 
Q8IIW6 Actin-like protein, putative 0.50 0.77 
Q8IIQ4 Actin-like protein homolog, ALP1 0.50 0.77 
Q8IBH5 Actin-like protein, putative 0.50 0.77 
Q8I4X0 Actin-1 0.50 0.77 
Q8I450 Actin-like protein, putative 0.50 0.77 
Q8I345 Actin-like protein, putative 0.50 0.77 
Q8I2A2 Actin-related protein, ARP1 0.50 0.77 
Q8I1V9 Actin-like protein, putative 0.50 0.77 
Q8IKV8 Sortilin, putative 0.48 0.45 
Q8I1S6 
Glutamyl-tRNA(Gln) amidotransferase 




Of the proteins predicted to bind to kakeromamide (1), actin and sortilin were 
deemed worthy of further evaluation given their higher predicted binding values. However, 
no in vitro sortilin assay is available. In contrast, actin polymerization assays are frequently 
employed to assess agents that affect actin dynamics, albeit using mammalian homologs 
of actin. Since 1 was predicted to bind to both Plasmodium and mammalian actin proteins 
but only mammalian actin assays are commercially available, an actin polymerization 
assay that uses pyrene-labeled rabbit muscle actin was employed. Several natural products 
are known to disrupt actin’s function by either inhibiting or stabilizing polymerization, 
which could arise from ligand binding.[67-70] Since apicomplexan actins (including those 
of Plasmodium) and mammalian actins are relatively divergent,[71] Plasmodium actin 
might be a useful molecular target. Additionally, since 1 did not exhibit toxicity towards 
human cell lines (Table 2), the predicted interactions with human actin apparently did not 
translate to a negative outcome for host cells, at least in vitro. The effect of 1 on rabbit 
actin polymerization was compared to the known actin polymerization inhibitor, 
latrunculin A. While latrunculin A suppressed polymerization at concentrations above 1.2 
µM (Figure 4A), 1 exhibited unique behavior with the highest tested concentration, 2.5 
µM, enhancing actin polymerization whereas the lowest tested concentration, 0.0025 µM, 
moderately suppressed polymerization relative to controls (Figure 4B). This suggests that 
1 causes a concentration-dependent modulation in mammalian actin function. Cyclic 
peptides such as phalloidin [67] from the death cap mushroom and jasplakinolide [70] from 
a marine sponge have been found to induce polymerization and stabilize actin filaments in 
a dose-dependent manner. Similar activity by 1 could be one possible explanation for the 
observed increase in actin polymerization with increasing concentrations of 1. Although 1 
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appears to impact mammalian actin polymerization, future tests evaluating the impact of 1 
on Plasmodium actin function would be worthwhile in order to further elucidate whether 
interactions with actin are relevant to this natural product’s mechanism of action on the 
malaria parasite. 
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Figure 4. Effect of positive control latrunculin A (A) and kakeromamide B (1) (B) 
on mammalian actin polymerization. Latrunculin A stopped actin polymerization at 
concentrations of 1.2 µM and above whereas 1 promoted actin polymerization at the 






Ulongamide A (2) was predicted to bind to one protein, an aspartyl protease, with 
mTC and precision values of 0.47 and 0.35, respectively. Aspartyl protease is involved 
with remodeling the erythrocyte by trafficking parasite proteins into erythrocytes, which 
ultimately aids the parasite in evading host recognition and response.[72] In fact, targeting 
aspartyl proteases in HIV has led to the development of clinically available antiretrovirals, 
which have also shown inhibition towards Plasmodium growth.[73] Taken together, 
aspartyl protease seems like a potentially promising target for 2. 
Lyngbyabellin A (3), the most potent antimalarial natural product isolated from 
Moorea producens in the current study, did not deliver any putative molecular targets via 
FINDSITEcomb2.0 protein-ligand binding calculations. Even a linear analog of 3, 
lyngbyabellin I,[57] was not predicted to bind to Plasmodium proteins. It is possible that 
the structural motifs of 3 are inadequately represented among ligands known to bind 
malarial proteins as sampled from the literature; however, 3 was predicted to bind to several 
human proteins. Thus, there exist compounds structurally similar enough to 3 in ligand 
databases to enable prediction of some protein binding events, but apparently not with 
Plasmodium proteins. We are, therefore, unable to propose hypotheses of possible 
molecular targets of 3. The promising selectivity of 3 towards Plasmodium, the availability 
of a total synthesis route, and the substantial collection of known lyngbyabellins warrants 
further study as a possible treatment option for malaria. 
1.4 Materials and Methods 
1.4.1 General Experimental Procedures 
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1H, COSY, HSQC, and HMBC NMR spectra were acquired on either a 16.4 T (700 
MHz for 1H and 175 MHz for 13C) Bruker Advance III HD instrument with a 5mm indirect 
broadband cryoprobe or an 18.8 T (800 MHz for 1H and 200 MHz for 13C) Bruker Avance 
III HD instrument equipped with a 3 mm triple resonance broadband cryoprobe. Spectra 
were recorded in CD3CN or CDCl3 and referenced to solvent residual peaks (δH 1.94 and 
δC 118.26 or δH 7.26 and δC 77.16, respectively). Spectra were processed and analyzed 
using MestReNova 12.0.0. Vacuum liquid chromatography (VLC) was performed using 
SiliCycle’s SiliaFlash F60, 40−63 μm silica gel. Supelco Supelclean ENVI-18 was used 
for solid-phase extraction (SPE). High-performance liquid chromatography (HPLC) 
separations were done with a Waters 1525 binary pump and either a Waters 2487 dual 
wavelength absorbance detector set at 254 nm or a Waters 2996 photodiode array detector, 
using two different columns: a 4.6 × 250 mm, C18-silica reversed-phase (Grace Alltima, 5 
μm particle size) and a 4.6 × 250 mm phenyl-hexyl phase (Phenomenex Luna, 5 μm particle 
size). High-resolution mass spectrometry (HRMS) data were collected with a 
ThermoFisher Scientific LTQ Orbitrap XL ETD spectrometer in positive ion mode. The 
masses of isolated natural products were estimated by quantitative NMR (qNMR) using a 
capillary filled with benzene-d6 as an internal standard that was placed inside an NMR 
tube containing a known amount of caffeine and tubes containing the identified compounds 
dissolved in the same amount of solvent.[74] 
1.4.2 Biological Material and Species Identification 
The dark purple marine cyanobacteria were found carefully organized into curtains 
covering snapping shrimp holes located on reef slopes offshore of Tuvuca Island in Fiji. 
The cyanobacteria were collected on September 25, 2007 from two separate locations (S 
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17°44.43′, W 178°39.155′ and S 17°30.546′, W 178°42.443′) and combined based on 
similarity in sample appearance and habitat. Voucher specimens identified as collection G-
0362 were stored at the University of the South Pacific and Georgia Institute of Technology 
in aqueous ethanol and formaldehyde. Bulk cyanobacterial sample was stored at the 
Georgia Institute of Technology in a −80 °C freezer. 
The cyanobacterium was identified as Moorea producens through morphological 
and 16S rRNA phylogenetic analyses. Briefly, the ethanol-preserved genomic DNA of 
cyanobacterial specimen G-0362 was extracted with the DNeasy Blood and Tissue kit 
(Qiagen) using the manufacturer’s protocol. Polymerase chain reaction (PCR) was utilized 
to amplify the single 16S rRNA gene fragment from genomic DNA using bacterial 16S 
rRNA primers, 27f, and 1492r.[75] A 25 μl reaction volume was used for PCR amplification 
with the following components: 200 μM of each dNTP, 50 ng of purified genomic DNA, 
1 μM of each oligonucleotide primer, 1.0 U Taq DNA Polymerase, and 1× Standard PCR 
reaction buffer (NEB, Ipswich, MA). A GeneAmp PCR system 2700 thermocycler 
(Applied Biosystems, Foster City, CA) was used to perform the PCR amplification with 
the following parameters for temperature cycling: 94 °C for 4 min for initial denaturation 
followed by 40 cycles of amplification (each cycle = denaturation for 50 s at 94 °C, primer 
annealing for 50 s at 55 °C, and primer extension for 2 min at 72 °C). The incompletely 
synthesized DNA underwent final extension at 72 °C for 7 min. Agarose gel 
electrophoresis (1% wt/vol) was used to analyze the PCR product, and an ethidium bromide 
stain was applied before the gel was visualized with a UV transilluminator. Forward and 
reverse primers were utilized to sequence the PCR product and the CAP3 Sequence 
Assembly Program was used to manually edit and assemble sequences.[76] The assembled 
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16S rRNA sequence (1338 bp) was submitted to GenBank (accession no. MN960022). The 
blastn program was used to assess the sequence similarity of the assembled contig of 
cyanobacterial 16S rRNA to other known cyanobacteria from Family Oscillatoriaceae by 
comparing it with the non-redundant nucleotide database (NCBI).[77] To determine the 
closest phylogenetically related species of Moorea producens, the 16S rRNA sequence of 
collection G-0362 was compared with those of known representatives from Family 
Oscillatoriaceae (Order Oscillatoriales) and Gloeobacter violaceous was included as a 
distant evolutionary taxon. MEGA X [78] was used for phylogenetic analysis using the 
Maximum Likelihood method based on the Kimura 2-parameter model [79] with 1000 
bootstrap iterations. 
1.4.3 Extraction and Isolation 
The cyanobacterial biomass (43 g) was freeze-dried (to 8.0 g) and exhaustively 
extracted (four times) using a 2:1 mixture of dichloromethane and methanol. The resulting 
crude extract (0.80 g) was purified by VLC with 80 mL of silica gel in a glass vacuum 
funnel (8 cm diameter by 9 cm high) with a glass frit. The fractions were collected using a 
stepped gradient of hexanes, EtOAc, and MeOH (nine fractions, 100% hexanes, 10% 
EtOAc/90% hexanes, 20% EtOAc/80% hexanes, 40% EtOAc/60% hexanes, 60% 
EtOAc/40% hexanes, 80% EtOAc/20% hexanes, 100% EtOAc, 25% MeOH/75% EtOAc, 
and 100% MeOH). The fractions eluting from 40% EtOAc/60% hexanes (14.1 mg), 60% 
EtOAc/40% hexanes (7.4 mg), 80% EtOAc/20% hexanes (5.8 mg), and 100% EtOAc (3.7 
mg) were further separated using reversed phase SPE (stepwise gradient of decreasing 
polarity starting with 15% MeOH in H2O to 100% MeOH, resulting in five fractions). 
Fractions 3, (50% MeOH in H2O, 2.4 mg), 4 (75% MeOH in H2O, 2.0 mg) and 5 (100% 
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MeOH, 4.2 mg) were subjected to C18-silica HPLC (50% MeCN/50% H2O held for 5 min, 
gradient from 50% MeCN/50% H2O to 100% MeCN from 5 to 40 min, and 100% MeCN 
from 40 to 60 min at 1 mL/min) to obtain nearly pure 1–5. Fractions containing 1 and 3 
underwent one more round of purification with C18-silica HPLC (60% MeCN/40% H2O 
+ 0.05% trifluoroacetic acid (TFA) held for 5 min, gradient from 60% to 70% MeCN from 
5 to 20 min, and 70% MeCN held from 20 to 25 min at 1 mL/min) to give 1 (tR = 17.5 min, 
18 µg) and 3 (tR = 12.2 min, 6.9 µg). The same C18-silica HPLC column was also used to 
purify 2 (isocratic method of 50% MeCN/50% H2O + 0.05% TFA held for 25 min at 1 
mL/min), resulting in pure 2 (tR = 18.5 min, 340 µg). A mixture containing 4 and 5 was 
purified using phenyl-hexyl silica HPLC (gradient from 80% MeOH/H2O to 90% 
MeOH/H2O over 20 min at 0.8 mL/min) to give 4 (tR = 14.5 min, 20 µg) and 5 (tR = 15.7 
min, 8.3 µg). The reported isolated yields do not include losses during separation or 
material subjected to bioassays and thus underestimate natural concentrations.  
Kakeromamide B (1): 1H and 13C NMR data, see Table 1; HRMS (ESI) m/z [M + 
H]+ calcd for C42H59N6O7S 791.4166, found 791.4150; [M + Na]
+ calcd for 
C42H58N6O7SNa 813.3985, found 813.3958. 
1.4.4 Antimalarial and Cytotoxicity Assays 
A standard method for evaluating antimalarial activity with asexual blood-stage P. 
falciparum and SYBR Green detection was used to assess the potency of extracts, fractions, 
and compounds.[80] Screening media was prepared from complete media supplemented 
with 0.05% Albumax II (but without human serum). Dr. David Fidock of Columbia 
University provided P. falciparum strain Dd2L, which was cultured with fresh O+ 
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erythrocytes (TSRI Normal Blood Donation). Compounds were transferred to assay plates 
using a Labcyte ECHO acoustic liquid handler. Fresh and parasitized erythrocytes were 
prepared in screening media before inoculating plates (Multi-Flo; BioTek, VT) with a final 
hematocrit of 2.5% and a final parasitemia of 0.3%. The assay plates were incubated for 
72 h in a chamber at 37 °C with a low oxygen gas formulation with daily gas exchanges. 
After incubation, a Multi-Flo liquid dispenser transferred SYBR Green lysis buffer to the 
wells, and the plates were incubated for another 24 h at room temperature to achieve 
optimal development of fluorescence signal, which was read by an Envision Multimode 
Reader (PerkinElmer, MA). Atovaquone, ganaplacide, and mefloquine were used as 
positive controls (EC50  = 0.00040, 0.0059, and 0.0029 μM, respectively). 
Activity against liver-stage P. berghei was quantified for extracts, fractions, and 
pure compounds using a slightly modified 48 h luminescence-based assay.[81] The salivary 
gland of infected Anopheles stephensi was dissected to harvest P. berghei-ANKA-GFP-
LucSMCON (Pb-Luc) sporozoites (originally received from Dr. Ana Rodriguez of NYU 
School of Medicine; last round of testing to evaluate pure 1, 3–5 used infected mosquitoes 
from Elizabeth Winzeler at UCSD and Dennis Kyle at UGA) which were filtered through 
a 20 μm nylon net filter twice (Steriflip, Millipore, MA), counted with a hemocytometer, 
and adjusted to achieve a final concentration of 200 sporozoites/1 μL in the assay media 
(DMEM without Phenol Red (Life Technologies, CA), 5% FBS, and 5 × Pen−Strep and 
glutamine (Life Technologies, CA)). A Multi-Flo (BioTek, VT) with a 1 μL cassette was 
used to transfer purified sporozoites, 1 × 103 sporozoites per well (5 μL), to assay plates 
containing HepG2 cells. After incubation at 37 °C for 48 h, a bioluminescence 
measurement was taken to assess the liver-stage growth. More specifically, media was 
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removed by inverting the plates, and spinning them at 150  g for 30 s, and 2 μL per well 
of BrightGlo (Promega, WI) was added for quantification of Pb-Luc viability. The 
luminescence was measured immediately after addition of the luminescence reagent using 
an Envision Multilabel Reader (PerkinElmer, MA). 
A previously described method was utilized to evaluate cytotoxicity against HepG2 
and HEK293T cells as a measure of general human toxicity.[82] Assay data generated for 
Plasmodium was analyzed with a Genedata Screener (v13.0-Standard). Inhibitors 
(puromycin for cytotoxicity and atovaquone for liver-stage parasites) were subtracted from 
neutral controls to normalize data. The Smart Fit function of the Genedata Analyzer 
generated dose-response curves that were used to calculate the half-maximal effective 
concentrations (EC50).  
1.4.5 Computational Binding Predictions 
FINDSITEcomb2.0 [46] was applied to screen cyanobacterial natural products against 
the whole genome of P. falciparum (isolate 3D7) (PF). FINDSITEcomb2.0 builds structural 
models using a threading approach by taking the protein amino acid sequence as input and 
applying TASSER refinement.[83] Models were built for 4,962 (92.5%) protein sequences 
out of a total of 5,364 PF sequences downloaded from UniProt (www.uniprot.org). For 
each target protein, the pockets were identified in their respective models and compared to 
the ligand-binding pockets located in PDB [84] structures as well as ChEMBL [85] and 
DrugBank [86] libraries. Pockets that best matched target pockets were selected, and their 
corresponding binding ligands were employed as template ligands. These template ligands 
were used for virtual screening as seed ligands for a given molecule with a fingerprint 
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comparison method to evaluate the binding probability of the molecule to the protein 
targets. The mTC virtual screening score, a measure of the similarity of the given molecule 
to the template ligands of a protein target in FINDSITEcomb2.0, was used to rank the targets. 
The mTC correlates with the likelihood of the protein target being a true target of the 
molecule, and its value ranges between 0 and 1 with 1 indicating the best fit. An mTC of 
0.5 corresponds to the expected precision of ~0.76 based on large scale benchmark 
statistics.[46] 
1.4.6 Actin Polymerization Assay 
The computationally predicted binding of 1 to actin was experimentally evaluated 
using a rabbit muscle actin polymerization assay kit from Abcam (kit ab239724) using the 
manufacturer’s protocol. Mean signal for n = 3 (actin polymerization control, solvent 
control, and background) or n = 2 (four different concentrations of latrunculin A and 
kakeromamide B (1)) replicates was acquired for time points taken every 30 s for 1 h on a 





CHAPTER 2. ECOLOGICAL ROLE OF THE RED ALGAL 




 This chapter is an expanded report of findings included in B.K. Chhetri, S. Lavoie, 
A.M. Sweeney-Jones, N. Mojib, V. Raghavan, K. Gagaring, B. Dale, C.W. McNamara, K. 
Soapi, C.L. Quave, P.L. Polavarapu, and J. Kubanek, Journal of Organic Chemistry, 2019, 
84(13), 8531-8541; https://pubs.acs.org/doi/10.1021/acs.joc.9b00884. Permission for 
reuse of portions of this publication was obtained from ACS and the letter granting reuse 
is included in Appendix B.  
2.1 Abstract 
In the underwater environment, many organisms make use of secondary metabolites 
for defense against consumers, competitors, and pathogens. For sessile organisms, 
chemical defenses are especially important: numerous examples exist of secondary 
metabolites from marine sponges and algae acting as feeding deterrents towards 
consumers, antimicrobials targeting the many pathogenic microbes that exist in seawater, 
allelopathic chemicals for competing with neighboring organisms for space in crowded 
reef environments, and antifouling agents that prevent biofouling on organismal surfaces. 
The red alga Peyssonnalia sp. produces a unique diterpene glycoside, peyssonnoside A (7), 
in relatively high abundance (0.42% of dry weight). Field and shore-based experiments 
exploring various ecological roles for this secondary metabolite led to a conclusion that 7 
functions as an antimicrobial defense, based on significant growth inhibition of the 
saprophytic marine fungus Dendryphiella salina when exposed to realistic concentrations 
of 7. Additionally, based on the lack of deterrence observed in antifeedant assays with a 
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generalist crustacean grazer and observed biofouling in field antifouling assays, there is no 
evidence that 7 functions as a chemical defense against herbivores or microbial fouling.  
2.2 Introduction 
The field of marine chemical ecology began several decades ago with the goal of 
understanding the biological roles of marine natural products by combining the expertise 
of natural product chemists and ecologists.[87] Natural products are genetically encoded 
for biosynthesis by specific organisms and exhibit specialized functions related to defense 
against consumers, competitors, pathogens, and biofoulers; settlement cues for larvae; and 
pheromones for mate finding.[88] Experimental methods to probe the roles of secondary 
metabolites have greatly benefited from the interdisciplinary nature of this field. For 
example, expertise of field ecologists informed the importance of applying ecologically 
relevant doses that represent realistic exposure of organisms to natural products while 
chemists provided valuable insight into which molecules are responsible for the observed 
interactions.[89]  
Natural products found in high abundance in organismal tissues are good candidates 
for testing hypotheses about possible ecological roles. An example of such a natural 
product is the novel diterpene glycoside peyssonnoside A (7) (Figure 5) isolated  from a 
red alga Peyssonnelia sp.[90] Chemical ecology experiments sought to answer if 7 acts as 
an antifeedant agent against an omnivorous generalist consumer, if 7 prevents the surface 
attachment of biofouling microbes, and/or if 7 inhibits growth of a marine fungus. For each 
experiment, realistic “enemies” were chosen to model the natural environment of 
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Peyssonnelia sp. and attempts were made to design experiments using near-natural 
concentrations of 7.  
 
 
Figure 5. Diterpene glycoside peyssonnoside A (7) isolated from the marine red 
alga Peyssonnelia sp.[90]  
 
2.3 Results and Discussion  
2.3.1 Evaluation of Antifeedant Properties  
Using a standard feeding assay,[26] peyssonnoside A (7) was evaluated for feeding 
deterrence against one generalist marine omnivore, the hermit crab Clibanarius striolatus. 
When incorporated into artificial diets at a concentration of 1.1 mg/ml, which is 20% the 
natural abundance of 7 in the alga, 7 was ineffective at deterring feeding by C. striolatus 
collected from an intertidal zone off Ono Island in Fiji: both control foods and food 
impregnated with 7 were consumed equally (Figure 6).  
Generalist consumers eat a wide variety of foods and are a good model to use when 
determining the presence of antifeedant properties since a molecule that deters a generalist 
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consumer will likely deter other consumers as well.[91] A specialist, on the other hand, has 
a much more limited diet and in some cases has evolved an ability to consume a food source 
that is deleterious to other consumers, such as the mollusc Stylocheilus striatus that feeds 
on cyanobacteria Lyngbya spp. that is toxic to generalist consumers.[92] Since 7 did not 
deter consumption by a generalist consumer, at least at the concentration tested, it likely 
does not have antifeedant properties against generalist consumers. The experiment could 
have been improved if a larger quantity of 7 had been available, enabling testing at full 
natural concentration. The nutritional content of the artificial food is also an important 
component of the experimental design as it should ideally match the nutritional content of 
the organism being modeled, in this case Peyssonnelia. For this experiment, the artificial 
food was assembled using a similar formulation to one devised for another type of calcified 
alga, Halimeda.[26] To determine the nutritional content of Peyssonnelia, the ash-free dry 
mass was calculated by combusting dried algal material in a furnace (114 mg/mL). This 
artificial food created for the feeding assay used an equivalent amount of the freeze-dried 
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Figure 6. Response of hermit crabs Clibanarius striolatus to food laced with 1.1 
mg/mL peyssonnoside A (7). These data indicate that 7 does not deter hermit crab feeding 
(mean ± standard error).[90]  
 
2.3.2 Surface Localization of Peyssonnoside A (7) 
Before evaluating whether 7 reduces surface fouling or exhibits antimicrobial 
properties against an ecologically relevant pathogen, an experiment was performed to 
determine if 7 is present on the surface of Peyssonnelia sp. A qualitative method similar to 
what was proposed by de Nys et al. that employed a hexane surface extraction indicated 
that 7 is in fact present on the surface of Peyssonnelia sp. (Figure 7), supporting its putative 
role in surface-mediated defense.[93] Hexane was chosen for the surface extraction because 
a short exposure (less than 60 seconds) minimizes damage to algal tissue, whereas other 
organic solvents typically lyse cells even during brief extraction. Since the collection of 
Peyssonnelia sp. contained individuals with various morphologies, surface extractions 
were performed on algal pieces ranging from highly calcified with a tan color to pieces that 
were very fleshy with a red to maroon color. This comparison revealed that fleshier algal 
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pieces with red coloration contained relatively more 7 than more highly calcified pieces 
(Figure 7), further supporting the surface defense hypothesis and additionally suggesting 
that more vulnerable tissues require greater amounts of 7 for protection, consistent with the 
optimal defense theory.[94,95] In addition to evaluating the presence of 7 on the surface of 
algal tissues, a preliminary experiment confirmed the partial extractability of 7 from a 
surface into hexanes, albeit only 0.11% of 7 was removed from a glass surface by hexanes 
while the remaining residue was removed with methanol. This suggests that the amount of 
7 extracted from the surface of Peyssonnelia sp. by hexane is only a small portion of what 
is present on the algal surface, further supporting the high surface abundance of 7 and the 





Figure 7. Extracted LC/MS chromatogram of m/z 531 corresponding to 7 and 
calculated peak area from surface extracts of Peyssonnelia sp. individuals ranging from 
heavily calcified (tan) to fleshy (red and maroon). The inset of each chromatogram reports 
the relative amount of each individual algal specimen extracted for LC/MS analysis 
expressed as a percentage of the total mass of algae analyzed in this experiment. Larger 
amounts of  7 were extracted from the surfaces of algal specimens with less observed 
calcification.   
 
2.3.3 Assessment of Peyssonnoside A (7) as an Antifouling Agent 
 Evaluation of whether 7 deters biofouling was accomplished using a modified 
version of the method presented by Henrikson and Pawlik.[96] In short, 7 was incorporated 
into a phytagel substrate at the same concentration used for the antifeeding assay, 1.1 
mg/mL, and paired with a solvent-only control which was then adhered to a petri dish. The 
petri dish was suspended in ocean water off the coast of Ono Island, Fiji, near a coral reef 
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where Peyssonnelia sp. naturally occurs, for a total of four days, exposing a natural 
community of fouling organisms to 7 in the field. The experiment was not of long enough 
duration to assess the settling of larval propagules and algae. Analysis of settled bacteria 
revealed that there was no significant difference in the amount of biofouling present on the 
surface of phytagel containing 7 versus a phytagel control without 7  (Figure 8).  
Although staining indicated that there was some microbial biofouling occurring 
within the four day experiment, there were several issues noted during the experiment that 
suggested an antifouling role for 7 should not be ruled out. First, growth of fouling 
organisms was not visible to the naked eye on phytagel surfaces after exposure to ocean 
water for four days, appearing similar to before the gels were submerged. Second, the stain 
used for determining the presence of cellular respiration on the surface of the gels, 2,3,5-
triphenyl tetrazolium chloride, is light-sensitive; the field setting of this experiment made 
it difficult to avoid light exposure during staining.  Thus, it is possible that the observed 
color change on stained phytagel resulted from light exposure rather than an indication of 
the presence of microbial biofoulers. Finally, attempts to extract RNA from gel samples  
preserved in RNAlater did not yield any RNA suggesting that settlement of biofoulers on 
the gels was negligible. One possible reason for the lack of biofouling on phytagel surfaces 
could be that the time period the gels were deployed was too short. Overall, there is no 
experimental evidence for an antifouling role but based on the high surface abundance of 
7, we suspect that a longer exposure period could have resulted in statistically significant 




Figure 8. Relative biofouling on phytagel surfaces treated with peyssonnoside A 
(7) and a paired solvent control, as indicated by the average color intensity with higher 
intensity values corresponding to higher microbial content (mean ± 1 standard deviation). 
Gels were hung in ocean water for 4 days before being removed, stained, and imaged.  
 
2.3.4 Antifungal Properties of Peyssonnoside A (7) 
When peyssonnoside A (7) was tested for antifungal effects on the saprophytic 
filamentous fungus Dendryphiella salina,[97] a dose-dependent inhibition of D. salina 
growth was observed with an IC50 of 0.14 µM (Figure 9). Considering that the natural 
abundance of 7 is 5.4 mg per mL of wet alga, inhibition of D. salina at a concentration of 
0.070 µg/mL indicates that 7 is both a potent and a highly abundant antifungal agent present 
in and on algal tissues. Microscopic imaging of media containing 7 indicated that this 
secondary metabolite promoted morphological changes consistent with an antifungal effect 
(Figure 9). Taken together with the high natural abundance of 7, these data are suggestive 
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Figure 9. Top: Growth inhibition of the fungus Dendryphiella salina by 
peyssonnoside A (7) compared to the known antifungal drug nystatin (n = 3, mean ± 
standard error). Bottom: Comparison of fungal growth in the presence of nystatin, DMSO, 
and 7 showing the morphological change in the fungal colonies exposed to 7.[90]  
 
Previous studies surveying the antimicrobial defenses of seaweeds have found that 
extracts and pure natural products from these marine organisms typically exhibit activity 
against one or more pathogenic marine microorganisms suggesting that this type of defense 
is fairly ubiquitous.[23,98,99] For the present experiment, D. salina was chosen for its global 
distribution in the marine environment; however, since it is a saprophytic fungus that 
breaks down dead and decaying organic matter, its relevance as a threat to live algae is 
uncertain. We failed to successfully culture the pathogenic fungus Lindra thalassiae, which 
would have been more relevant for evaluating the defensive properties of 7 against disease-
causing fungi. Limited studies suggest that antifungal marine natural products that inhibit 
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D. salina also inhibit L. thalassiae [23,100] meaning that even without data from additional 
fungi, 7 may function as a general antifungal agent.   
2.4 Materials and Methods 
2.4.1 Specimen Collection 
Peyssonnoside A (7) was isolated from Peyssonnelia sp. (G-1163) collected on 
March 17, 2012 from Singi Locale, Tetepare Island, Solomon Islands (S 842.561’, E 
157⁰26.500’) and Peyssonnelia sp. (G-1588) collected on June 17, 2017 off Uepi Island, 
Solomon Islands (S 826.549′, E 157⁰56.695′).[90]  Peyssonnelia sp. co-occurs with the 
organisms used for the ecological experiments detailed in this chapter. 
2.4.2 Surface Extraction 
Before evaluating if 7 was present at the surface of Peyssonnelia sp., solubility of 
7 in hexanes, the solvent chosen for surface extraction,[93] was assessed. A solution 
containing a small amount of 7 was added to a glass scintillation vial and dried. Two mL 
of hexanes was added to the scintillation vial, shaken for 30 seconds, and transferred to a 
clean vial. Both vials were dried then redissolved in methanol for LC/MS evaluation. 
Comparison of the chromatographic peak area for 7 removed by hexanes versus the 
residual 7 remaining in the original scintillation vial revealed that 0.11% of 7 was removed 
by hexanes, which was sufficient for detection by LC/MS.  
A collection of Peyssonnelia sp. (G-1588) known to contain 7 was chosen for 
evaluation of the surface localization of 7. Morphological variations related to the level of 
calcification were noted and as a result, five distinct algal individuals were selected, 
ranging from heavily calcified with minimal red pigment to red and maroon colored leaves 
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with little calcification. The individual samples were patted dry to remove excess moisture 
without damaging the surface of the tissue, weighed, and then added to a scintillation vial 
containing 2 mL of hexanes. The samples were agitated for 30 seconds and then removed. 
The remaining solution was dried, redissolved in methanol, and evaluated by LC/MS. The 
peak associated with 7 (m/z 531) was extracted from each chromatogram to determine if 7 
was present and if the morphological characteristics impacted the relative amount extracted 
from the surface of the algal specimen. 
2.4.3 Ash-free Dry Mass Measurement 
After measuring the wet mass of Peyssonnelia sp. G-1588 (1.62 g), the alga was 
freeze-dried resulting in a dry mass of 1.30 g (80% of the wet mass). The dried algal pieces 
were ground with a mortar and pestle, weighed, and evenly distributed to five different 
porcelain crucibles. The crucibles were placed in a Fisher Scientific Isotemp Muffle 
Furnace set to 450 °C for 6 hours.[26] The remaining ash was measured and subtracted 
from the starting dry mass to obtain the ash-free dry weight (22.7 ± 0.3 mg, n=5, 9.0% of 
the starting dry mass). This value was divided by the volume of the alga (1.0 mL total, 0.20 
mL per replicate) subjected to ash-free dry mass analysis to approximate nutritional content 
(114 mg/mL).  
2.4.4 Antifeedant Assay 
Artificial food was prepared using a mixture of molten agar (0.02 g/mL) and Ulva 
sp. (100 mg/mL), a green alga palatable to a wide range of marine herbivores, incorporated 
into window screen.[26] Peyssonnoside A (7) was dissolved in 0.48 mL methanol and added 
to 10 mL of the artificial food, resulting in a final concentration of 1.1 mg/mL which is 
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approximately 20% of the natural concentration of 7, lower than its actual abundance in 
algal tissue but still a considerably high concentration for a natural product. The full natural 
concentration was not used due to constraints on the total amount of natural product 
available for ecological studies. Control foods were prepared by using an equivalent 
amount of solvent in the artificial food mix. One square containing artificial food with 7 
and a second square with the control food were placed in deli dishes housing hermit crabs 
(2 food squares per deli dish) (Figure 10). After approximately 50% of the control or treated 
food available to any given hermit crab was consumed, the food-containing window 
screens were removed and analyzed for total amount consumed of each treatment by 
counting the number of empty squares versus total that started with food, analyzing with a 
two-tailed t-test. Replicates where crabs ate less than 10% or more than 90% of the total 
food available to them were excluded. Of the 36 crabs housed individually for the assay, 
16 produced usable results. 
 
   
Figure 10. Feeding assay design using the hermit crab C. striolatus, consuming 
artificial food incorporated into a square of window screen (left). The resulting output of 
the feeding assay was window screen squares with varying degrees of artificial food 
consumed by the crab (right; “treatment” condition refers to artificial food with the addition 
of 7).  
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2.4.5 Antifouling Assay 
Peyssonnoside A (7) or methanol (solvent control) was incorporated into phytagel 
(n = 5 for each condition) and hung for four days off a floating dock in Oneta Bay off Ono 
Island, Fiji (18°53'07.3"S, 178°30'39.6"E) (Figure 11). Phytagel was prepared at the field 
site by adding 1.5 g of phytagel powder to 50 mL of boiling tap water (0.03 g/mL). 
Peyssonnoside A (7) was dissolved in 0.30 mL methanol and added to 6 mL of hot phytagel 
solution (final concentration 1.7 mg/mL; 30% of natural concentration). This mixture was 
split into five replicates applied to window screen squares adhered to the surfaces of petri 
dishes (Figure 11). Solvent controls were prepared using an equivalent ratio of methanol 
to phytagel and the resulting gels were applied to a second petri dish glued to the one 
containing 7. The petri dishes were tied to a rope before being deployed under the floating 
dock for 4 days. After removal from the field, the plates were sprayed with a 1% (w/v) 
solution of 2,3,5-triphenyl tetrazolium chloride, which is a colorless water-soluble dye 
reduced to the red, insoluble compound formazan by respiration-dependent enzymatic 
processes in cells.[101,102] Images were taken of each gel from the same distance and 




    
Figure 11. Experimental set-up to evaluate if peyssonnoside A (7) prevented 
fouling on the surface of phytagel submerged in ocean water for four days. Gels were 
adhered to window screen (for quantification purposes) that was attached to petri dishes 
(left image) with paired controls prepared in a similar fashion and attached to the back of 
the plate containing gel infused with 7. Plates were deployed under a floating dock off Ono 
Island, Fiji, for 4 days (right image).  
 
2.4.6 Antifungal Assay 
Fungal culture was grown at 24 °C in 790 By+ medium (1.0 g/L yeast extract, 1.0 g/L 
peptone, 5.0 g/L D-(+)-glucose, in 1 L of seawater). A tissue grinder was used to 
homogenize fungal hyphae before distributing D. salina in 790 By+ media to a sterile 96-
well plate. The antifungal assay was performed with a 1:1 serial dilution ranging from 
0.0070 µM to 0.94 µM for 7, much lower than the natural concentration of 7 in 
Peyssonnelia sp. which is 10mM.[90]   Nystatin was used as positive control at 
concentrations of 0.14 µM to 0.0010 µM. After three days, relative cell concentrations 
were measured as turbidity using a BioTek ELx800 Absorbance Microplate Reader at 600 
nm. Percent growth inhibition at each concentration was calculated relative to fungus 
exposed to solvent (DMSO). Images were recorded using a dissecting microscope to 
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confirm that elevated optical density readings corresponded to fungal growth. The growth 
inhibition data were fit to a sigmoidal dose-response curve using GraphPad and the IC50 of 




CHAPTER 3. DISCOVERY OF ANTHELMINTIC 






Although more than 500 million people suffer from hookworm infections per year 
worldwide with observed resistance to all available anthelmintic drugs, research into new 
therapeutic agents has been neglected. Collaboration with the Aroian lab at the University 
of Massachusetts Medical School resulted in identification of a mixture of cyanobacterial 
natural products from a cyanobacterial collection that exhibited potent and reproducible 
hookworm inhibition. Extracts, semi-purified chromatographic fractions, and near-pure 
natural products reproducibility decreased hookworm survival and motility, an indicator of 
deleterious effects on the worm’s neuromuscular system which is a viable drug target. 
Efforts are currently ongoing to identify and characterize natural product(s) within the 
mixture responsible for the observed anthelmintic activity.  
3.2 Introduction 
According to a survey of neglected tropical disease experts, there is consensus that 
current drugs, vaccines, and vector controls are not adequate for the elimination of soil-
transmitted helminth (STH) infections, including those caused by hookworms.[22] 
Infectious worms emerge from contaminated soil, invade a human host by penetrating the 
skin, establish themselves in the host’s intestines, and cause illness and disability 
associated with diminished nutritional status such as growth retardation, anemia, and 
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cognitive impairment.[103] In the past decade, five prevalent neglected tropical diseases 
(NTDs) including those caused by STHs were prioritized by the World Health 
Organization (WHO) and the international community as targets for eventual eradication 
as a global health problem.[104,105] This decision provided opportunities to develop and 
deploy treatments for diseases that had otherwise been underfunded since they 
disproportionately impact impoverished regions and result in morbidity more often than 
death. Partnerships established between public and private entities have resulted in success 
in controlling some NTDs including lymphatic filariasis, trachoma, and 
onchocerciasis, especially through use of mass administration of drugs and infection 
surveillance of impacted areas, although the low efficacy of currently available 
anthelmintic compounds (Figure 12) and the evolution of resistance have presented 
challenges in control of STH infections.[106-111] Additionally, inadequate sanitation often 
leads to reinfection necessitating periodic de-worming, providing further opportunity for 
drug resistance.[112-114] In order to effectively control STH infections in vulnerable human 
populations long term, it is imperative that new anthelmintic therapeutics are added to the 
drug discovery pipeline to combat the rising incidence of resistance and improve efficacy 




Figure 12. Molecular structures of currently available drugs for the treatment of 
infectious hookworms.[115-117] 
 
Assessing pure compound or extract libraries for anthelmintic properties has been 
hindered by the low-throughput nature of STH assays and lack of validation to ensure 
proposed screening systems accurately predict activity against adult STHs responsible for 
the disease burden while minimizing false positives and false negatives.[118] Adult STHs 
are obligate parasites that require a host for survival, complicating assay design and 
resulting in low-throughput pipelines for screening of drug candidates. High-throughput 
screening assays using C. elegans, which are free-living nematodes that are easier to 
maintain, have been associated with a high false negative rate. This is attributed to C. 
elegans having a genome optimized for host-free survival for the duration of its lifespan 
which improves biotransformation and elimination of anthelmintic drugs bydetoxification 
enzymes.[119] From evaluation of multiple screening methodologies (including use of 
several life stages of C. elegans and the hookworm Ancylostoma ceylanicum ),[118] an 
assay that used the free-living egg-to-larval (E2L) stage of A. ceylanicum for screening a 
library of 1280 approved drugs most accurately predicted efficacy against adult 
hookworms while minimizing the number of false negatives. Additionally, the E2L stage 
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provides an advantage for drug screening since it can be accessed from feces of infected 
(hamster) host rather than by host dissection. Hits identified in the E2L screen led to a 
higher false positive rate than other screening methods necessitating a secondary screen 
with adult infectious worms to confirm relevant anthelmintic compounds.  
Anthelmintic hits from a marine organism extract library at Georgia Tech were 
identified via the aforementioned screening methodology. Use of this multi-step screening 
approach enabled exploration of an extract from a mixed collection of cyanobacteria with 
promising activity against both larval and adult stages of hookworm.  Efforts are currently 
ongoing to characterize natural products present in the worm active fractions from this 
collection. 
3.3 Results 
3.3.1 Screen for Anthelmintic Activity 
E2L screening of 324 extracts from a diverse array of marine organisms collected in 
Fiji and the Solomon Islands resulted in identification of 68 extracts that inhibited egg 
hatching or impaired larval development of the hookworm A. ceylanicum (Table 4). Of 
these, ten were prioritized based on availability of adequate field-collected sample for 
bioassay-guided fractionation of extracts and on a lack of prior literature reports of natural 
products associated with its taxonomic group. Of the ten prioritized organisms, a collection 
containing a mixture of cyanobacterial species (sample G-0978) exhibited promising 
activity against E2L and adult hookworms in subsequent follow-up screening while the 
other nine collections exhibited weak or no activity against E2L worms after scaled-up 
extraction of field-collected samples. Further separation of the extract using liquid/liquid 
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partitioning revealed that the dichloromethane-soluble extract fraction was the most potent 
with inhibition of E2L worms at 1.25 µg/mL and substantial reduction in motility of adult 
hookworms, as indicated by an average motility index of 1.2 after 24 hours and 0.80 after 
48 hours (Table 5). 
. 
Table 4. Collections identified as hits (68 total from 324 extracts screened) in 
preliminary E2L Ancylostoma ceylanicum hookworm screening of the Georgia Tech 
marine organism extract library. Extracts were considered hits if they produced full or near-
full inhibition of egg hatch or larval development at 5 µg/mL. Bolded collections were 
selected for further evaluation based on availability of field-collected samples for natural 
product isolation as well as taxonomic interest. 
Collection Identifier Taxonomy 
G-0998 ascidian Polyandrocarpa  polypora 
G-0910 cyanobacterium Lyngbya sp. 
G-0913 red alga Peyssonnelia sp. 
G-0914 cnidarians Eleutherobia sp. 
G-0920 green alga Tydemania expeditionis 
G-0923 unknown cyanobacterium 
G-0932 green alga Tydemania expeditionis 
G-0950 brown alga Lobophora sp. 
G-0951 sponge Axinyssa sp. 
G-0956 sponge Acanthella cavernosa 
G-0964 sponge Hippospongia sp. 
G-0967 sponge Halichondria sp. 
G-0976 sponge Axinyssa sp. 
G-0978 mixed cyanobacterial collection 
G-0979 unknown sponge 
G-0980 sponge Diacarnus spinipoculum 
G-0984 sponge Dysidea sp. 
G-0990 green alga Valonia aegagropila 
G-0991 sponge Dysidea sp. 
G-0995 unknown sponge 
G-1000 sponge Dysidea sp. 
G-1004 red alga Peyssonnelia sp.  
G-1006 sponge Haliclona sp. 
G-1009 unknown sponge 
G-1018 unknown sponge 
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Table 4 (continued) 
 
G-1025 red alga Laurencia sp. 
G-1046 unknown sponge 
G-1047 cnidarians Rumphella suffruticosa 
G-1048 sponge Phyllospongia sp. 
G-1049 sponge Coscinoderma mathewsi 
G-1054 sponge Acanthella cavernosa 
G-1056 green alga Caulerpa sp. 
G-1058 sponge Jaspis sp. 
G-1085 sponge Diacarnus spinipoculum 
G-1093 green alga Tydemania expeditionis 
G-1098 sponge Axinyssa sp. 
G-1103 sponge Haliclona sp. 
G-1106 unknown sponge 
G-1116 unknown sponge 
G-1120 sponge Thorecta sp. 
G-1122 sponge Dysidea sp. 
G-1131 sponge Dictyodendrilla sp. 
G-1146 cnidarians Junceella sp. 
G-1147 sponge Axinyssa sp. 
G-1149 cnidarian Briareum sp. 
G-1150 red alga Amphiroa sp. 
G-1152 sponge Dysidea sp. 
G-1153 sponge Lamellodysidea sp. 
G-1154 sponge Dysidea sp. 
G-1156 unknown sponge 
G-1159 unknown sponge 
G-1163 red alga Peyssonnelia sp.  
G-1173 unknown sponge 
G-1174 sponge Spongosorites sp. 
G-1177 sponge Ianthella basta 
G-1178 unknown sponge 
G-1184 sponge Dysidea sp. 
G-1186 sponge Aka sp. 
G-1188 sponge Agelas sp. 
G-1190 sponge Callyspongia sp. 
G-1192 sponge Callyspongia sp. 
G-1193 unknown foraminifera 
G-1196 sponge Callyspongia sp. 
G-1197 sponge Axinyssa sp. 
G-1198 sponge Axinella sp. 
G-1202 sponge Cladocroce sp. 
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Table 4 (continued) 
 
G-1226 unknown sponge 
G-1229 sponge Thorecta sp. 
 
 
Table 5. Activity of extracts from cyanobacterial collection G-0978 against the E2L 
and adult stages of the hookworm Ancylostoma ceylanicum. The dichloromethane-soluble 
extract fraction from G-0978 exhibited the most promising activity against A. ceylanicum. 
For E2L screening, black shading indicates full or near-full inhibition of egg hatch or larval 
development at the indicated concentration while gray means only partial inhibition. The 
average motility index for adult hookworm screening is based on qualitative observations 
made for six individual worms with the following assignments: 0 – dead worm; 1 – motile 
after stimulation by touch; 2 – motile; and 3 – highly motile.  
 
A. ceylanicum E2L Screening 
Concentration (µg/mL) 
A. ceylanicum Adult 
Screening Average 
Motility Index  
(10 µg/ml, n=6 
worms) 






crude extract  
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3.3.2 Taxonomic Characterization of G-0978 
The cyanobacterial collection was tentatively identified as Symploca sp. based on 
morphological examination (Figure 13). However, analysis of the DNA voucher specimen 
by Bhuwan Chhetri and Dr. Nazia Mojib of the Kubanek lab using 16S rRNA phylogenetic 
analysis revealed that collection G-0978 is in fact a mixture of different cyanobacterial 
species. Although 16S rRNA was successfully amplified from the genomic DNA extracted 
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from the specimen G-0978 (Figure 14), initial sequencing reactions were unsuccessful. 
Upon analysis of the chromatograms, there were multiple peaks suggesting presence of 
more than one genotype, reflecting the existence of more than one cyanobacterial species 
in the collection. With multiple attempts and separate sequencing reactions, use of reverse 
primer 1492r produced four different 16S rRNA sequences of ~250 bp. The resulting 
phylogenetic tree indicates that sequences 1-3 are more closely related to each other than 
the other known cyanobacterial species (Figure 15). Additionally, sequence 4 is a unique 
species that does not cluster with any of the other species in the phylogenetic tree. The 
cyanobacteria of this phylogenetic tree fall into different cyanobacterial subsections, which 
are classifications based on morphological differences.[120] Halothece sp. and 
Chroococcidiopsis sp. are unicellular cyanobacteria that belong to subsections I and II, 
respectively. Leptolyngbya sp., Oscillatoria salina, and Prochlorothrix sp. all belong to 
subsection III which consists of filamentous cyanobacteria of varying morphological 
complexity. The clustering of filamentous cyanobacteria with unicellular species in the 
phylogenetic trees is attributed to the polyphyletic origins within filamentous 
cyanobacteria.[121] Comparison of known morphologies with taxonomic information in the 
hierarchical cluster resulted in identification of Symploca as the most morphologically 
similar to the tuft-like structure observed in collection G-0978 (Figure 13). However, since 
the species identified from collection G-0978 are in distinct clusters in the phylogenetic 
tree, they are most likely not Symploca and might instead belong to either a genus of 





    
Figure 13. Photograph of a tuft from the cyanobacterial collection G-0978 soon 




Figure 14. Agarose gel (1% w/v) displaying the PCR product (~1.4 kb) amplified 
from genomic DNA of the specimen G-0978 using bacterial 16S rRNA primers, 27f and 
1492r. The first lane shows the DNA molecular weight marker (Fast DNA ladder, NEB). 





Figure 15. Phylogenetic relationship of marine cyanobacteria from collection G-
0978 with top cyanobacterial species matched from blastn search by 16S rRNA sequences 
using the Maximum Likelihood method based on the Kimura 2-parameter model in MEGA 
X. The percentage of replicate trees in which the associated species clustered together in 
the bootstrap test (1000 iterations) is shown next to the branches. The accession numbers 
of the 16S rRNA of respective cyanobacteria are mentioned in parentheses. The branch 
lengths are calculated by the number of substitutions per site and the tree is portrayed to 
scale. This analysis was performed by Dr. Nazia Mojib. 
 
3.3.3 Isolation and Dereplication of Natural Products in Anthelmintic Extract Fractions  
To determine if any previously characterized natural products were present in the 
worm-active dichloromethane(DCM)-soluble extract fraction (as a form of dereplication), 
it was evaluated by proton nuclear magnetic resonance (NMR) spectroscopy as well as 
low-resolution mass spectrometry (MS). The NMR spectral data contained signals 
indicative of peptides while the MS data suggested the presence of several known natural 
products including the anticancer cyclic hexadepsipeptide veraguamide G,[122] the 
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neurotoxic cyclic depsipeptide hoiamide B,[123] and the antimitotic tetrapeptide belamide 
A.[124] Since none of these natural products have previously been evaluated for 
anthelmintic activity, the DCM-soluble extract fraction underwent bioassay-guided 
fractionation to isolate the molecule(s) responsible for the observed bioactivity (Figure 16). 
Separation with normal phase silica column chromatography resulted in 25 fractions. Due 
to limits on the number of adult hookworms available for screening, only a subset of 
fractions, including some combined fractions, were tested. The fraction AMS04001-2, 
comprised of materials that eluted at 98% DCM/2% methanol (MeOH) and 96% DCM/4% 
MeOH, exhibited promising activity against adult A. ceylanicum with a 48 hour average 
worm motility index of 0.17. Fraction AMS04001-2 was further separated using normal 
phase high-performance liquid chromatography (HPLC), resulting in 28 fractions. NMR 
and LC/MS spectral data were acquired for each of these fractions before recombining 
fractions (again, due to bioassay testing limitations) and evaluating against adult A. 
ceylanicum. Fractions eluting between 23 and 36 minutes (fractions 20-26) had a 24 hour 
average worm motility index of 0.8 and a 48 hour average worm motility index of 0.2 when 
tested with adult A. ceylanicum hookworms. NMR and LC/MS spectral data acquired for 
fractions 20-26 (Figure 17, Figure 18, and Table 6) indicated that each fraction either was 
nearly pure or contained a mixture of six or fewer natural products with NMR spectral 
features suggestive of peptide natural products. Also, searching the LC/MS data for masses 
corresponding to veraguamide G, hoiamide B, and belamide A revealed that these natural 
products were not present in the worm-active HPLC fractions, raising the possibility that 
these fractions contain previously undiscovered natural products. The Aroian lab is 






















Figure 16. Separation scheme for bioassay-guided fractionation of the worm active 
cyanobacterial collection (G-0978) identified in screening against the hookworm A. 
ceylanicum. Green circles describe the chemical separation step, red boxes indicate which 
fractions were submitted for testing against hookworms, and yellow boxes are fractions 
identified as worm-active. Due to bioassay testing constraints, not every fraction was tested 
and in some cases, fractions were combined (e.g. HPLC fractions 1-6, 7-19, and 20-26 






Figure 17. 1H NMR spectral data for hookworm-active HPLC fractions 20-26 from 




Figure 18. Low-resolution mass spectrometry data for hookworm-active HPLC 





Table 6. Mass spectral features present in the low-resolution electrospray LC/MS 




Mass Spectral Features 
AMS03141-20 [M+H]+ = m/z 418.93 
[M+Na]+ = m/z 440.92 
[2M+Na]+ = m/z 859.16 
[M+H]+ = m/z 543.95 
[M+H]+ = m/z 558.94 
AMS03141-21 [M+H]+ = m/z 349.88 
[M+H]+ = m/z 354.78 
[M+H]+ = m/z 398.94 
[M+H]+ = m/z 419.03 
[M+H]+ = m/z 433.12 
[M+Na]+ = m/z 455.01 
[2M+Na]+ = m/z 887.03 
AMS03141-22 [M+H]+ = m/z 334.89 
[M+H]+ signals that are 
m/z 18 apart = m/z 
443.11, m/z 461.20, m/z 
479.19, m/z 497.18  
[M+Na]+ = m/z 518.87 
[M+H]+ = m/z 691.83 
[M+Na]+ = m/z 713.81 
AMS03141-23 [M+H]+ = m/z 331.89 
[M+H]+ = m/z 363.77 
[M+H]+ = m/z 399.84 
[M+H]+ = m/z 545.75 
AMS03141-24 [M+H]+ = m/z 334.59 
[M+H]+ = m/z 398.94 
[M+H]+ = m/z 420.93 
[M+H]+ = m/z 424.93 
AMS03141-25 [M+H]+ = m/z 334.89 
[M+H]+ = m/z 499.08 
AMS03141-26 [M+H]+ = m/z 334.89 
[M+H]+ = m/z 370.96 
[M+H]+ = m/z 398.94 
[M+H]+ = m/z 419.03 
[M+H]+ = m/z 696.03 




Although there are no cyanobacterial natural products previously reported to be 
active against infectious worms, earlier mechanistic studies provide insight for how these 
compounds might inhibit parasitic worms, especially when compared to known 
mechanisms of action of other anthelmintic compounds. The benzimidazole anthelmintics 
albendazole (8) and mebendazole (9) have been found to selectively inhibit microtubule 
synthesis by selectively binding to nematode β-tubulin at the colchicine site which blocks 
tubulin polymerization.[125,126] This adversely effects worms by interrupting formation of 
spindle fibers needed for cell division and by disrupting cytoplasmic microtubules involved 
in nutrient uptake. Also, poor host tissue absorption of these compounds from the digestive 
tract minimizes toxic side effects while still effectively targeting parasites. Antimitotic 
cyanobacterial peptides such as dolastatin 10 (12) [127] and belamide A (13) [124] (Figure 
19) have been reported to disrupt microtubule networks through interactions with β-
tubulin. Thus, it is possible that these cyanobacterial natural products might also act as 
anthelmintics. Although the natural products present in the worm-active fraction from the 
cyanobacterial collection G-0978 appear to have peptide-like features, mass spectral 
signatures expected for 12 ([M+H]+ m/z 785.5029) and 13 ([M+H]+ m/z 605.3643) are not 
present in the low-resolution LC/MS data. The 1H NMR spectral data, however, includes 
signals suggestive of methyls, N-methyls, aromatic protons, NHs, and α-protons, structural 
moieties that are also present in 12 and 13 which suggests that the anthelmintic natural 




Figure 19. Cyanobacterial natural products that disrupt microtubule networks, one 
possible mechanism for anthelmintic activity.[124,127] 
 
Other known targets of anthelmintic compounds are ion channels. For example, the 
anthelmintic drugs levamisole and pyrantel act as a nicotinic acetylcholine agonists that 
cause paralysis in worms by prolonged excitation at neuromuscular junctions.[128] The 
freshwater cyanobacterium Anabaena flos-aquae produces alkaloid neurotoxins anatoxin-
a and homoanatoxin-a that act as nicotinic acetylcholine agonists;[129] however, examples 
of natural products from marine cyanobacteria with this type of activity are not represented 
in the literature. The natural product hoimamide A, a cyclic depsipeptide from the marine 
cyanobacterium Lyngbya majuscula, interacts with voltage-gated sodium channels and 
activates sodium influx in mouse neocortical neurons.[130] Identifying natural products that 
target sodium channels has been of interest for identifying possible analgesic therapeutics 
and treatments for neurodegenerative disorders. Given that nematodes, including 
hookworms, possess potassium and calcium channels instead of sodium channels,[131] 
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studies to identify natural products that target sodium channels will most likely not translate 
to anthelmintic activity.    
3.5 Next Steps and Future Directions 
The current work exhibits the successful application of a multi-step screen for 
hookworm activity and the use of bioassay-guided fractionation to obtain nearly pure 
natural products present in an anthelmintic fraction. Once hookworm bioassay results are 
received from the Aroian lab, final purification steps will be performed to obtain pure 
natural product(s) that will undergo full structural characterization techniques such as 2D 
NMR spectroscopy and high-resolution mass spectrometry. Pure, quantified natural 
product will be quantitatively evaluated against adult hookworms to determine 
anthelmintic potency and their mechanisms of action will be explored.  
3.6 Materials and Methods 
3.6.1 General Experimental Procedures 
1H NMR spectra were acquired on a 16.4 T (700 MHz for 1H and 175 MHz for 13C) 
Bruker Avance III HD instrument with a 5 mm indirect cryoprobe. Spectra were recorded 
in CDCl3 and referenced to the solvent residual peak (δH 7.26) and spectra were processed 
and analyzed using MestReNova 12.0.0. Column chromatography was performed using 
SiliCycle’s SiliaFlash F60, 40−63 μm silica gel. High-performance liquid chromatography 
(HPLC) separations were achieved with a Waters 1525 binary pump and a Waters 2996 
photodiode array detector using either a 4.6 × 250 mm silica column (Phenomenex Luna, 
5 μm particle size) or a 10 x 250 mm silica column (Waters Spherisorb Silica OBD Prep 
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Column, 5 μm particle size). Low-resolution mass spectrometry (HRMS) data were 
collected in positive ion mode using a Waters QDa spectrometer.  
3.6.2 Biological Material and Species Identification 
Tough bunches of a purple marine cyanobacteria with a white interior were 
collected from reef rubble in a lagoon off Ono-i-Lau, Fiji on August 7, 2011 (S 20°37.12′, 
W 178°44.24′). Voucher specimens identified as collection G-0978 were stored at the 
University of the South Pacific and Georgia Institute of Technology in aqueous ethanol 
and formaldehyde. Bulk cyanobacterial material was stored at the Georgia Institute of 
Technology in a −80 °C freezer.  
Genomic DNA from both ethanol-preserved and bulk frozen cyanobacterial 
specimen (G-0978) was extracted using the DNeasy Blood and Tissue kit (Qiagen) 
according to the manufacturer's protocol. The single 16 rRNA gene fragment from genomic 
DNA was amplified via the polymerase chain reaction (PCR), using bacterial 16S rRNA 
primers, 27f and 1492r.[75] The PCR amplification was performed in a 25 μl reaction 
volume consisting of 50 ng of purified genomic DNA; 200 μM of each of the dNTPs; 1 
μM of each of the oligonucleotide primers and 1.0 U Taq DNA Polymerase, and 1× 
Standard PCR reaction buffer (NEB, Ipswich, MA). The PCR amplification was performed 
in a GeneAmp PCR system 2700 (Applied Biosystems, Foster City, CA) thermocycler 
using the following temperature cycling parameters: initial denaturation at 94°C for 4 min 
followed by a total of 40 cycles of amplification in which each cycle consisted of 
denaturation at 94°C for 50 s, primer annealing at 55°C for 50 s and primer extension at 
72°C for 2 min. After amplification, final extension of the incompletely synthesized DNA 
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was carried out at 72°C for 7 min. The PCR product was analyzed by agarose gel 
electrophoresis (1% wt/vol). The gel was stained with ethidium bromide and visualized 
under a UV transilluminator. The PCR product was sequenced with forward or reverse 
primers, and sequences were manually edited. The sequence similarity of the 
cyanobacterial 16S rRNA to other known cyanobacteria was determined by comparing it 
with the non-redundant nucleotide database (NCBI) using the blastn program.[77] MEGA 
X[78] was employed to conduct phylogenetic analysis using the Maximum Likelihood 
method based on the Kimura 2-parameter model[79] with 1000 bootstrap iterations. 
3.6.3 Extraction and Isolation 
Cyanobacterial biomass (2339 g) was freeze-dried (849 g) and exhaustively 
extracted (four times) using a 1:1 mixture of dichloromethane and methanol. The resulting 
crude extract (79.3 g) was separated by liquid/liquid partition resulting in hexane (18.5 g), 
dichloromethane (4.7 g), and butanol/water (45.4 g) soluble fractions. The DCM-soluble 
fraction was subjected to silica column chromatography with 279 g of silica gel in a (40 
cm diameter by 550 cm high) column with a glass frit. The fractions were collected using 
a stepped gradient of DCM and MeOH (13 fractions, 100% DCM, 99% DCM/1% MeOH, 
98% DCM/2% MeOH, 97% DCM/3% MeOH, 96% DCM/4% MeOH, 95% DCM/5% 
MeOH, 94% DCM/6% MeOH, 93% DCM/7% MeOH, 92% DCM/8% MeOH, 91% 
DCM/9% MeOH, 90% DCM/10% MeOH, 50% DCM/50% MeOH, 100% MeOH). The 
fractions eluting from 96% DCM/4% MeOH (2.18 g) and 95% DCM/5% MeOH (46.4 mg) 
were further separated using semi-prep silica HPLC (90% hexanes/10% ethyl acetate held 
for 5 minutes, gradient from 90% hexanes/10% ethyl acetate to 100% ethyl acetate from 5 
to 55 minutes, held 100% ethyl acetate for 5 minutes at 4 mL/min).  
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3.6.4 Anthelmintic Assays 
3.6.4.1 Hookworm Developmental Screening (E2L) 
Initial screening for anthelmintic activity was performed using an egg-to-larva 
(E2L) hookworm development screen.[118] Briefly, infectious Ancylostoma ceylanicum 
larvae (L3i) were orally administered to immunosuppressed male Syrian hamsters and after 
18 days, worm eggs were isolated from feces. Eggs were transferred to a 96-well plate pre-
coated with an E. coli food source, test conditions were added, and plates were incubated 
for 7 days at 28 °C. Inhibition of egg hatch or larval development were used to assess the 
inhibitory effect of test conditions. 
3.6.4.2 Adult Hookworm In Vitro Screening 
Hamsters infected with A. ceylanicum were dissected 11 days post-infection to 
retrieve young adult worms from the hamster’s small intestine.[118] Worms were washed 
with prewarmed medium three times (RPMI1640, 100 µg/ml streptomycin, 100U 
penicillin, 10 µg/ml amphotericin) before being transferred to a 96-well screening plate 
with 97 µl of medium (3 worms per well). Marine organism extracts and fractions were 
dissolved in DMSO and added to screening plates at a final concentration of 5 µg/mL.  
After incubation at 37 °C and 5% CO2 for 24 hours, inhibition of worms was assessed using 
the standard motility index.[132] The index ranked worm motility from 0 to 3 with 0 
indicating dead worms, 1 corresponding to worms that exhibit movement after stimulation, 
2 for moving worms, and 3 for highly active worms. Treatment conditions that resulted in 
a motility index of 1 or less for at least two worms were considered inhibitory. For each 
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treatment condition, six worms were tested and subjectively assigned a motility index value 




CHAPTER 4. METABOLOMICS ANALYSIS OF THE IMPACT 
OF CLADOPHOROL D FROM THE GREEN ALGA 






An increasing incidence of infections by antibiotic-resistant bacteria and a dearth of 
new treatment options in the development pipeline necessitates the discovery of new 
antibiotics. An important component in this development is understanding the mechanism 
of action (MOA) of novel drug leads as this information allows for intelligent deployment 
of antibiotics. The objective of the present study was to identify putative MOAs of a novel 
antibiotic oligomeric polyphenol, cladophorol D, isolated from a green alga Cladophora 
socialis, using LC/MS and NMR-based metabolomics to chemically profile methicillin-
resistant Staphylococcus aureus (MRSA) treated with this new natural product compared 
with nine antibiotic pharmaceuticals with different known MOAs. Currently, the 
experimental design for this project has been completed and pilot experiments confirming 
the design have been conducted but cladophorol D (17) exposure experiments and 
metabolomics analyses have yet to be finished.    
4.2 Introduction 
In the United States, more than 35,000 people die annually from more than 2.8 million 
infections caused by antibiotic-resistant bacteria and fungi.[133] One Gram-positive 
antibiotic-resistant bacterium, methicillin-resistant Staphylococcus aureus (MRSA), has 
been classified as a serious threat by the CDC due to its resistance to many first-line 
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antibiotics. Unfortunately, since major pharmaceutical companies have shrunk or 
abandoned their antibiotic discovery programs, there are few antibiotics in the development 
pipeline, causing concern that the rise of evolved resistance among bacterial pathogens is 
outpacing the advancement of new treatment options.[134] In early 2020 the World Health 
Organization warned of the threat of antibiotic resistance as a result of the drying drug 
pipeline as well as the concern that the majority of drugs currently in development are 
variations on existing antibiotics with only a handful addressing the most serious drug-
resistant infections.[135] Pursuing analogs of current antibiotics is limited by the number of 
modifications that can be made to a single chemical core.[136] Additionally, analogs are 
more likely to target the same pathways as the parent compound making them more 
susceptible to encountering bacterial resistance due to cross-resistance with existing 
antibiotics. Currently, only 10 of the 41 antibiotics in development represent either a new 
drug class or target a new mechanism of action.[137] Understanding the mechanism by 
which newly discovered antibiotics target bacteria is a necessary step for mitigating the 
possible evolution of resistance and for expanding the approaches by which we control 
these pathogens, such as by use of combination therapies.[138] Identifying combinations of 
drugs through such approaches as checkerboard assays helps prioritize promising treatment 
options by exploring synergistic interactions of compounds against bacteria and by 
discovering antibiotic mixtures that thwart bacterial resistance pathways.[139,140] 
Metabolomics has recently expanded with technological advancements in detection 
methods, data processing capabilities, and database availability.[141] Simultaneous analysis 
of many metabolites (small molecule intermediates or end products of metabolism) enables 
evaluation of phenotypic differences among cells, tissues, organs, or organisms exposed to 
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different conditions.[32] Due to its ability to provide selective, rapid, and sensitive analysis 
of metabolites, mass spectrometry (MS) has been the technique of choice for the vast 
majority of recent metabolomics studies.[142] MS detects readily ionized metabolites 
present in the submicromolar range and below, and it has both better resolution and a larger 
dynamic range compared to other available techniques. The disadvantages of MS include 
poor uniformity and repeatability of results arising from inconsistent sample preparation, 
ionization, and chromatography. Failure of some molecules to ionize, suppression of 
ionization by other components present in complex biological matrices, and a lack of 
quantitativeness are further weaknesses. Another widely used option for metabolomics, 
nuclear magnetic resonance (NMR) spectroscopy, requires minimal, non-destructive 
sample handling to quantitatively detect the most abundant metabolites but NMR is not 
particularly sensitive, failing to detect metabolites in the submicromolar range.[143] Signal 
overlap due to limited spectral dispersion is another weakness of NMR spectroscopy, 
particularly with 1H NMR, however other NMR approaches with greater ability to resolve 
overlapping resonances (e.g., J-resolved spectroscopy; HSQC; TOCSY; and those 
detecting nuclei other than 1H) suffer from even weaker sensitivity. 1H-based NMR 
techniques only detect molecules with non-exchangeable protons so metabolites that 
contain few protons or primarily exchangeable protons are poorly sampled by NMR-based 
metabolomics. Vibrational spectroscopy techniques (e.g., Fourier transform infrared 
spectroscopy and surface-enhanced Raman spectroscopy) are additional options for 
metabolomics studies which are less expensive and have a higher throughput than MS and 
NMR but are limited by their relatively poor specificity and sensitivity.[144] Despite the 
variety of available options for chemically profiling metabolomes, no single approach 
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detects all metabolites in a sample. Several recent publications have suggested that 
combining multiple methods, for example NMR spectroscopy and MS, can help overcome 
limitations of a single analysis type while improving detection and structural 
characterization of metabolites and expanding the coverage of the metabolome.[142,145] 
NMR and MS are complementary techniques that expand the measurable metabolome by 
detecting different metabolites in addition to some metabolites in common, allowing for 
both confirmation of compound identities by multiple methods as well as detection of a 
greater number of metabolites.[146,147] Additionally, NMR and MS have undergone 
substantial technological advancements in instrumentation and are widely accessible to 
research groups, making them preferred analytical tools for the metabolomics community. 
Thus, combining multiple analytical techniques and connecting the resulting datasets is the 
optimal approach for improving confidence in metabolite assignments and increasing the 
total number of features detected in the metabolome.    
Metabolomics shows special promise for the evaluation of drug mechanism of action 
(MOA).[30] Metabolomics provides a wealth of information about the effects of drugs on 
a pathogen by surveying thousands of metabolites that are the result of complex 
biochemical pathways.[148] This information provides a global snapshot of how an 
antibiotic affects pathogen phenotype. The pathogen of interest for the present study, 
Staphylococcus aureus, has been the focus of numerous investigations on how strains 
respond metabolically to various antibiotic classes, providing useful information about 
changes in biochemical pathways that occur upon exposure to different drugs.[149-151] 
Metabolomics has also been employed to evaluate the MOA of novel antibiotics by 
comparison to drugs with fully characterized MOAs or by annotating all metabolite 
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perturbations to identify impacted pathways in cases where the compound acts via a new 
mechanism.[148,152] 
The antibiotic oligomeric polyphenols, cladophorols A – I (14–22) (Figure 20), were 
isolated from a Fijian green alga, Cladophora socialis, and identified using a combination 
of NMR spectroscopy, mass spectrometric analysis, and computational modeling with DFT 
calculations.[153] Polyphenols are not commonly found in green algae; only a few 
examples exist of related green algal natural products including the brominated 
polyphenolic feeding deterrent avrainvilleol and its condensation product, rawsonol [154-
156] as well as two vanillic acid analogs from Australian Cladophora socialis that disrupt 
insulin cell signaling.[157] When evaluated against a panel of Gram-positive and Gram-
negative bacteria and two pathogenic fungi, cladophorols B (15), C (16), D (17), E (18), F 
(19), and G (20) showed selectivity towards MRSA with MIC90 values of 13 ± 2, 1.4 ± 0.3, 
9 ± 2, 25 ± 3, 14 ± 3, and 31 ±3 µg/ml, respectively.[153] Cladophorol B (15) was also 
active against blood-stage P. falciparum with an EC50 of 1.9 µg/ml. These natural products 
exhibited weak cytotoxicity against immortalized human keratinocytes at concentrations 
well above those at which MRSA was susceptible, indicating that the antibiotic 
cladophorols could be viable antibiotics for further pharmaceutical development due to 




Figure 20. Molecular structures of phenolic natural products isolated from the green 
alga Cladophora socialis.[153] 
 
Although broad spectrum antibiotics are often preferred, their use poses increased risk 
for evolution of drug resistance and can also have negative consequences for human 
microbiomes, which provide essential physiological functions to their human hosts and 
which are sensitive to antibiotic exposure.[158] Disruptions to the microbiome can result in 
disrupted nutrient absorption, vitamin production, and immune response and can also lead 
to lowered bacterial diversity, increasing susceptibility to opportunistic pathogens such as 
Clostridium difficile. In cases where the identity of the infection-causing bacterium is 
known, application of a narrow spectrum antibiotic, such as the MRSA-selective 
cladophorol natural products, can avoid some of these issues. Selectivity towards a few 
strains of one species of bacterial pathogen suggests that the cladophorols have a specific 
MOA. For the present study, cladophorol D (17) was chosen for evaluating the MOA of 
this class of natural products against MRSA using a metabolomics-based approach due to 
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compound availability and the relatively high potency of 17 against MRSA. Additionally, 
a strain of S. aureus resistant to 17 was identified (unpublished results from C. Quave’s 
lab) which allows for future studies comparing the sensitive MRSA strain in order to 
identify possible mechanisms of resistance.   
4.3 Experimental Design 
4.3.1 Development of Intracellular Metabolite Extraction Procedure 
Since there is no universal method in microbial metabolomics for growing or 
processing bacterial samples, different procedures reported in literature were evaluated to 
identify techniques that maximize metabolite yield while minimizing media components, 
metabolite  losses,  and chemical changes among metabolites caused by sample processing. 
The first consideration was the type of media that would be used for growing MRSA. 
Relative to typically used complex growth media, a previous study found that growth of 
MRSA on minimal media resulted in a metabolite profile indicative of survival mode.[159] 
To avoid putting cells in such a state which would confound experimental exposure to 
antibiotics, the complex media Nutrient Broth was selected. Two practices commonly used 
for separating bacterial cells from media, fast-filtration and centrifugation, have been found 
to differently impact cellular stress, with centrifugation resulting in greater stress.[151,160] 
To minimize the production of stress metabolites, fast filtration was selected for the current 
experiment. Another important factor for metabolite extraction is the quenching step which 
should be reproducible, fast, and prevent leakage of intracellular metabolites prior to 
addition of extraction solvent. A number of methods have been used to quench metabolism 
of bacterial cells including immersion in cold methanol, cold ethanol, perchloric acid, or 
68 
 
glycerol-saline solutions, and dipping cells in liquid nitrogen.[161] Cold ethanol was chosen 
for the current experiment. For cell disruption, required to access the intracellular 
metabolites, a mechanical method is preferred since organic solvents are often not 
sufficient for breaking open the cell wall of S. aureus.[160] Bead beating with zirconia/silica 
beads was used to access intracellular metabolites. An overview of the experimental design 
is provided in Figure 21.  
 
 
Figure 21. Experimental design for extraction and analysis of intracellular 






4.3.2 Selection of Antibiotics 
A total of nine clinically relevant antibiotics with a variety of mechanisms of action 
(MOAs) were selected for inclusion in the metabolomics experiment to determine putative 
MOAs by which cladophorol D (17) acts as an antibiotic (Table 7, Figure 22). Antibiotic 
concentrations were selected so that MRSA growth would be suppressed by 20-50% 
relative to MRSA treated with a solvent control. Inhibiting MRSA growth by greater than 
50% might result in the production of metabolites associated with cellular death while 
inhibition less than 25% might not cause detectable metabolite perturbations or could 
possibly promote production of metabolites associated with cell signaling.[148,162] The 
optimal antibiotic concentration was determined by comparing the growth of MRSA 





Table 7. Antibiotics selected for inclusion in the metabolomics study to determine 
the MOA of cladophorol D (17), by comparison with antibiotics of known MOA.  






fluoroquinolone Inhibits cell division by interfering with 
DNA gyrase and a type II 
topoisomerase, topoisomerase IV, 




water lincosamide Binds to the 23S RNA of the 50S 
subunit of the bacterial ribosome 
resulting in inhibition of bacterial 
protein synthesis.[164] 
isoniazid (25) water pyridine 
carboxylic acid 
Disrupts bacterial cell wall by 
inhibiting synthesis of mycolic 
acids.[165,166] 
kanamycin (26) water aminoglycoside Binds to the 30S subunit of the 
bacterial ribosome resulting in 
inhibition of protein synthesis.[167] 
linezolid (27) water oxazolidinone Inhibits initiation process of protein 
synthesis. [168] 
monensin (28) ethanol ionophore Acts as an ionophore by interfering 
with cell membrane permeability.[169] 
rifampicin (29) dimethyl 
sulfoxide 
ansamycin Inhibits DNA-dependent RNA 
polymerase, leading to a suppression of 
RNA synthesis and cell death.[170] 
sulfacetamide 
(30) 
methanol sulfonamide Interferes with biosynthesis of folic 
acid by competitively binding to 
bacterial para-aminobenzoic acid 




water glycopeptide Complexes with D-Ala-D-Ala terminal 
of peptide chain resulting in inhibition 




Figure 22. Nine antibiotics [163-165,167-172] included in MRSA metabolomics study 





4.4.1 Evaluation of Cladophorol D (17) against S. aureus Strains 
To probe the selectivity of cladophorol D (17) and to identify resistant strains of S. 
aureus, experiments were performed by Dr. Cassandra Quave’s lab at Emory University 
to evaluate activity of 17 against multiple S. aureus strains. This testing indicated that 17 
inhibits three of five strains of S. aureus tested, including a methicillin-resistant strain of 
S. aureus (AH1263) and two multi-drug resistant (MDR) strains provided by the CDC 
(CDC474 and CDC480) (Figure 23). Two strains, a methicillin-sensitive S. aureus 
(UAMS1) and an MDR strain resistant to tetracycline and susceptible to oxacillin 
(CDC470), were resistant to 17, making them viable options for pursuing a metabolomics 
study comparing the metabolome of sensitive versus resistant S. aureus in the presence of 






























Figure 23. Evaluation of cladophorol D (17) against multiple strains of 
Staphylococcus aureus (UAMS1: osteomyelitis methicillin-sensitive S. aureus (ATCC 
49230); AH1263: MRSA strain regularly used by the Quave lab; CDC470: a multidrug-
resistant (MDR) S. aureus strain resistant to tetracycline and susceptible to oxacillin; 
CDC474: an MDR S. aureus strain susceptible to tetracycline and resistant to oxacillin; 
CDC480: an MDR S. aureus strain resistant to both tetracycline and oxacillin). Data 
generated by Dr. Cassandra Quave’s lab at Emory University.  
 
4.4.2 Evaluation of Antibiotics with Known MOAs 
Before starting the metabolomics experiment, each selected antibiotic was 
evaluated against an in-house strain of MRSA (ATCC 33591) to determine their IC50 and 
MIC90 values (Table 8, Figure 24). Since IC50 and MIC90 values are impacted by 
experimental conditions, it was important to experimentally obtain these measurements 
while using reported literature values as a starting point. Of the antibiotics tested, MRSA 
strain ATCC 33591 was relatively insensitive to clindamycin (24), isoniazid (25), and 
sulfacetamide (30). Since these antibiotics act via unique MOAs, they were included in the 
experiment despite their relative lack of inhibition against MRSA, which could be 
anticipated to result in modest, if any, disruption to the MRSA metabolome.  
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Figure 24. Growth inhibition of MRSA treated with nine antibiotics in a 96-well 
microplate. Growth of this strain of S. aureus (ATCC 33591) was not inhibited by exposure 
to clindamycin (24), isoniazid (25), or sulfacetamide (30) treated with a maximum 
concentration of 650, 650, and 320 µg/mL, respectively.  
 
Table 8. IC50 and MIC90 values measured for the nine antibiotics chosen for the 






ciprofloxacin (23) 0.12 0.39 
clindamycin (24) > 650 > 650 
isoniazid (25) > 650 > 650 
kanamycin (26) 0.34 0.93 
linezolid (27) 0.160 0.64 
monensin (28) 0.33 0.57 
rifampicin (29) < 0.00023 < 0.00064 
sulfacetamide (30) > 320 > 320 
vancomycin (31) 0.55 0.84 
 
The results of the antibiotic dose response experiment were subsequently used to 
choose concentrations to evaluate at the culture volume planned for the metabolomics 
experiment. More specifically, the goal was to identify concentrations that inhibited MRSA 
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growth relative to a solvent control by between 20 and 50%. This range was chosen so that 
the effect of a given antibiotic on the MRSA metabolome could be observed while 
minimizing the amount of dead cells, which could skew results by focusing on metabolites 
associated with catabolism and cell death. Since the culture environment varied drastically 
from the initial evaluation performed in 96-well plates, the concentrations selected did not 
result in ideal MRSA growth suppression for all of the antibiotics tested in scaled-up 
preliminary experiments (Figure 25). Additionally, the dose response curve for some of the 
antibiotics exhibited very steep slopes, indicating great sensitivity to minute differences in 
antibiotic concentration. Ciprofloxacin (23), monensin (28), and vancomycin (31) 
produced optimal MRSA growth inhibition between 20 and 50% at 0.050, 0.35, and 0.25 
µg/mL, respectively. Isoniazid (25) and rifampicin (29) did not suppress MRSA growth 
sufficiently at any tested concentrations with the highest concentrations tested being 1.5 
mg/mL and 0.23 ng/mL, respectively. Since 25 did not suppress MRSA growth at any 
concentration tested in the 96-well plate format (maximum concentration of 650 µg/mL), 
there will likely not be an observable reduction of MRSA growth with this antibiotic. 
Therefore, the concentration of 1.5 mg/mL for 25 will be used for the metabolomics 
experiment. Clindamycin (24), kanamycin (26), linezolid (27),  and sulfacetamide (30) 
suppressed MRSA growth too much at the concentrations tested. For the antibiotics that 
did not achieve ideal growth curves at any of the tested concentrations, a follow-up 
experiment was performed to identify optimal antibiotic concentrations (Figure 26). 
Additionally, cladophorol D (17) was included in this evaluation. Results from the follow-
up growth curve experiment identified the following optimal concentrations: 0.45 mg/mL 
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for clindamycin (24), 0.10 µg/mL for kanamycin (26), 0.15 µg/mL for linezolid (27),  0.50 













































































































































































































































































































































































































Figure 25. MRSA growth curves exposed to each of nine antibiotics (selected for 
the metabolomics experiment). Optical density (OD) readings at 600 nm were recorded 
regularly over the course of 6.5 hours to track growth of MRSA, with higher OD values 
indicating greater cell density. The goal was to achieve a final OD reading for the antibiotic 
treatment conditions that was between 50-80% of the maximum signal obtained for MRSA 
treated with a solvent control. 
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Figure 26. Follow-up evaluation of MRSA growth exposed to adjusted 
concentrations of the antibiotics clindamycin (24), kanamycin (26), linezolid (27),  
rifampicin (29), and sulfacetamide (30) as well as cladophorol D (17).  
 
4.4.3 Preliminary Evaluation of Metabolomics Workflow with Four of the Nine 
Antibiotics 
Before performing a full scale metabolomics experiment with cladophorol D (17), 
a pilot experiment was executed using a subset of the antibiotics to confirm that the steps 
shown in Figure 21 produce results that discriminate between the different treatment 
conditions. For each condition, a total of six replicates were included, with two replicates 
of each treatment generated each day for three days (i.e., in three batches). After 
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intracellular metabolite extraction, 1H NMR spectral data were collected on an 800 MHz 
NMR spectrometer for both nonpolar and polar metabolites using CDCl3 and phosphate 
buffered D2O, respectively. The spectral data for the nonpolar metabolites contained few 
resonances in regions of the spectrum illustrative of important functional groups, instead 
revealing substantial methyl and methylene envelopes indicating the presence of fatty acids 
which are not distinguishable by NMR spectroscopy; these features did not vary among 
treatments. Thus, statistical analyses were not performed for this data set pertaining to 
lipid-soluble metabolites.  
Spectra from the polar metabolomes exhibited a greater number of complex 
resonances and, by eye, appeared to vary by treatment (Figure 27). The NMR spectral data 
for the polar metabolites were pre-processed using Metabolab and statistically analyzed 
with PLS Toolbox. A principal component analysis (PCA) was employed to detect 
relationships between exposure to different antibiotics and features of the MRSA 
metabolome (Figure 28, Figure 29).   Evaluation of PCA results indicated that although the 
treatment conditions were not distinguishable according to the first principal component 
(PC1), there was obvious separation between conditions in PCs 2, 3, and 4. Polar 
metabolomes of MRSA exposed to ciprofloxacin and monensin were statistically different 
from the other conditions via PC2 and were distinguishable from each other in PC3. PC4 
revealed differences between the vancomycin treatment and sulfacetamide and the solvent 
control. Metabolomes associated with sulfacetamide exposure heavily overlapped with the 
solvent control which supports the previously observed minimal impact sulfacetamide had 




Figure 27. 1H NMR spectra (phosphate buffered D2O, 800 MHz NMR) of 
intracellular metabolite extracts from MRSA treated with ciprofloxacin (red), monensin 
(green), sulfacetamide (purple), vancomycin (orange), or a solvent control (black). 
 
Examination of PCA loadings for PCs 2, 3, and 4 enabled preliminary consideration 
of MRSA metabolites whose concentrations were affected by antibiotic exposure (Figure 
29). Variability in metabolite abundances among treatments arose from differences in 
NMR spectral signals between 1-4 ppm and 7.5-8.5 ppm. There is a wide variety of 
metabolites with proton spectral signals in the 1-4 ppm range, including lipids, sugars, 
amino acids, lactic acid, and acetate, while signals in the 7.5-8.5 ppm range might 
correspond to protons in purine, aromatic groups, or the amino group of an amino 
acid.[173,174] For PC 2, spectroscopic features with positive loadings were associated with 
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metabolites that have increased concentrations in MRSA treated with either ciprofloxacin 
or monensin. NMR spectral signals around 1.5, 1.9, 2.1, 2.4, 3.2, 3.4, 3.9, 7.7 and 8.4 ppm 
were all noticeably upregulated in PC 2. Positive loadings in PC 3 corresponded with 
increased concentrations of metabolites from treatment of MRSA with ciprofloxacin while 
negative loadings were associated with increased concentrations of metabolites in the other 
treatment conditions. Interestingly, some of the spectral signals with positive loadings in 
PC 2 were negative in PC 3, including 1.9, 3.2, 3.4, 3.9, 7.7, and 8.4 ppm, suggesting that 
their presence in the positive region of PC 2 was due to monensin. Additionally, PC 3 
contained a higher concentration of the metabolite corresponding to the signal at 2.4 ppm 
which suggests this metabolite corresponds to treatment of MRSA with ciprofloxacin. PC 
4 differentiated treatment of MRSA with vancomycin, ciprofloxacin, or monensin from 
treatment of MRSA with sulfacetamide or the solvent control. The loadings plot for PC 4 
looked very similar to the loadings for PC 2 with only slight differences: 0.9 ppm was 
negative in PC 4 (absent in PC 2), 1.5 ppm had variance in both positive and negative 
directions (only positive in PC 2), and 3.2 ppm was absent in PC 4. Comparison of 1H 
NMR spectral signals of extracts from MRSA treated with ciprofloxacin to the loadings 
plot for PC 3, which differentiated ciprofloxacin from the other treatment conditions, 
revealed positive peaks in the loadings plot corresponded to observable 1H NMR spectral 
signals (Figure 30). Although NMR metabolomics produced results that showed 
differentiation between treatment conditions, additional analysis using mass spectrometry 
would aid in identification of metabolites. Thus, for the full metabolomics experiment 
exploring the MOA of cladophorol D (17), both NMR spectroscopy and LC/MS will be 




Figure 28. Principal component analysis (PCA) scores plots of metabolomics data 
from 1H NMR spectra of polar, intracellular metabolites from MRSA (ATCC 33591) 
treated with either ciprofloxacin (n=4), monensin (n=5), sulfacetamide (n=4), vancomycin 
(n=5), or a solvent control (n=5). Colored circles correspond to the 95% confidence interval 











Figure 29. A. PCA loadings for 1H NMR metabolomics of polar, intracellular 
extracts of MRSA (ATCC 33591). Spectroscopic features with positive loadings are 
associated with metabolites exhibiting increased concentrations in treatments that fall in 
the positive region of the scores plot (i.e., ciprofloxacin and monensin treatments for PC 
2) whereas spectroscopic features with negative loadings indicate metabolites with 
increased concentrations corresponding to treatments that fall in the negative region of the 
scores plot (i.e., sulfacetamide, vancomycin, and solvent control treatments for PC 2). B. 
Overlay of loadings plots from PC 2 (red), PC 3 (orange), and PC 4 (black) in NMR spectral 







Figure 30. Overlay of loadings plot for PC 3 with NMR spectral data acquired for 
intracellular metabolite extracts from MRSA treated with ciprofloxacin, the treatment 
differentiated by PC 3. Positive loadings values correspond to NMR spectral signals that 
are upregulated in the ciprofloxacin treatment condition. 
 
4.5 Discussion 
Of the available techniques for evaluating mechanisms of action (MOA), a systems 
biology approach, such as metabolomics, is one of the most efficient and comprehensive 
options when the MOA of a candidate drug is completely unknown, especially when 
compared to approaches that assess one putative MOA at a time. The global picture 
provided by omics approaches allows for a fuller appreciation of perturbations to cellular 
pathways associated with exposure to a drug. Of the omics approaches, metabolomics 
measures the end products of biochemical pathways and can amplify minor changes that 
occur in the transcriptome, proteome, or genome.[141] Another situation where 
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metabolomics proves to be the best analysis option for understanding the MOA of available 
drugs is in cases where the target pathogen has poorly understood biology or a complex 
infection cycle, which makes an unbiased approach for exploring MOA more suitable than 
targeted methods.[175] Mycobacterium tuberculosis is one such pathogen that presents both 
of these challenges which is in part why recent MOA studies of this pathogen employ 
metabolomics.[148,152] Although the biology of S. aureus is better understood than M. 
tuberculosis, a metabolomics approach is still considered a powerful tool for elucidating 
MOA of novel antibiotics.    
A simple approach to decipher whether a novel antibiotic acts via a known or new 
MOA is to compare metabolomes of the pathogen exposed to the novel antibiotic vs. 
antibiotics whose MOAs have previously been characterized. If the novel drug induces 
pathway perturbations that overlap with a known antibiotic’s, this supports the hypothesis 
that the two antibiotics share a common MOA against the target pathogen. This approach 
was successfully applied in a study of Mycobacterium smegmatis, a non-pathogenic 
bacterium used as a model for M. tuberculosis, in which the effects of three novel chemical 
leads with unknown MOAs were compared to 12 antituberculosis drugs with known 
MOAs.[148] Through principal component analysis (PCA) and orthogonal partial least-
squares discriminant analysis (OPLS-DA) of 1H NMR spectral data, that study reported 
that the new drugs shared a common MOA with one another. Metabolomes of M. 
smegmatis exposed to these drugs also clustered with those treated with the antibiotics 
ampicillin, D-cycloserine, and vancomycin, all of which disrupt cell wall formation, 
supporting the hypothesis that the new drugs also disrupt cell wall formation. In the present 
study, a similar approach is planned to determine if the novel antibiotic natural product 
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cladophorol D (17) acts against MRSA via an MOA in common with one of nine antibiotics 
with known MOAs. The pilot experiment with the antibiotics ciprofloxacin, monensin, 
sulfacetamide, and vancomycin confirmed that an NMR-based metabolomics approach 
distinguishes metabolite differences in MRSA treated with these different antibiotics. 
Comparison of the 1H NMR spectral signals responsible for the observed variance in 
antibiotic treatment conditions to NMR metabolomics studies presented in literature 
allowed some conclusions to be drawn. Ciprofloxacin has previously been reported to alter 
the pool of deoxynucleotides and peptidoglycan precursors, ultimately impacting DNA and 
cell wall synthesis.[150] 1H NMR spectral signals for deoxyribose sugars fall within the 
spectral range of 1-4 ppm where differences were observed for PC 3 (principal component 
that differentiated ciprofloxacin from the other treatment conditions); however, downfield 
signals (6-8 ppm) associated with protons of the base unit of a deoxynucleotide were absent 
in this loadings plot, disproving the hypothesis that MRSA exposure to ciprofloxacin 
disrupted deoxynucleotides in the current experiment (Figure 29). A previous study 
reported that metabolites associated with the tricarboxylic acid cycle, including citrate, 
isocitrate, and 2-oxoglutarate, were upregulated during treatment of S. aureus with 
ciprofloxacin. PC 3 contains increased NMR spectral signals corresponding to these 
molecules.[150] Evaluation of the impact of monensin on cattle ruminal fluid, which 
contains a diverse array of microbes, found that metabolic pathways associated with 
metabolism of linoleic acid and some amino acids, including phenylalanine, are 
upregulated.[176] PC 2, which differentiated monensin and ciprofloxacin from the other 
treatment conditions, contained upregulated signals in both the upfield (1-4 ppm) and 
downfield (7.5-8.5 ppm) regions that might correspond to these types of metabolites. The 
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next step for this project will be to perform the full metabolomics experiment with all nine 
antibiotics and cladophorol D (17), combining NMR and MS-based metabolomics 
analysis. 
If the metabolome of MRSA treated with cladophorol D (17) does not overlap with 
one of the other antibiotic treatments, another approach that can be taken to elucidate a new 
antibiotic’s MOA is to examine which metabolites are upregulated or downregulated, 
without comparing to other known drugs. This information can be used to determine which 
biochemical pathways are impacted by any individual antibiotic. A study evaluating the 
effect of antibiotics against Escherichia coli successfully employed untargeted mass 
spectrometry-based metabolomics to characterize the MOAs of nine antibiotics, supporting 
that this is a viable approach for elucidating unknown and possibly novel MOAs.[177]  
Comparing responses of related bacterial strains to an antibiotic is another possible 
approach for assessing MOA. By comparing metabolomes of strains from the same 
bacterial species with varying susceptibility to a given antibiotic treatment, it is possible to 
identify subtle differences indicative of how the antibiotic inhibits growth of a more 
sensitive strain. Additionally, this approach may lead to identification of mechanisms of 
resistance that have led to a susceptible strain becoming insensitive. This approach is 
complementary to the method presented in the current work as both methods provide 
information about what biochemical pathways are perturbed. This method was successfully 
used to evaluate S. aureus strains with varying degrees of susceptibility to the antibiotics 
methicillin, gentamicin, ciprofloxacin, erythromycin, and fusidic acid, leading to the 
finding that certain lipid groups are upregulated in resistant bacterial strains conferring 
antibiotic resistance to the bacteria.[178] The screening against S. aureus strains performed 
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by Dr. Cassandra Quave’s lab pinpointed sensitive and resistant bacteria that could be used 
for a future study of bacterial resistance pathways relevant to cladophorol D (17). 
4.6 Materials and Methods 
4.6.1 Determination of Antibiotic Dosage for Metabolomics 
MRSA (ATCC 33591) was grown at 37 °C with shaking at 120 rpm in 10 mL of 
Difco Nutrient Broth overnight. Optical density at 600 nm (OD600) was measured (BioTek 
ELx800 Absorbance Microplate Reader) and culture was diluted to obtain an OD600 of 
0.030 (approximate cell density 1 x 108 cells/mL). MRSA culture was distributed to wells 
in a 96-well plate and the following antibiotics were added in serial dilution down the plate 
along with solvent controls based on the solubility of each antibiotic: ciprofloxacin 
(dissolved in 0.5% aqueous acetic acid, concentration range 0.015-33 µg/mL), clindamycin 
(water, 0.015-650 µg/mL), isoniazid (water, 0.015-650 µg/mL), kanamycin (water, 0.015-
33 µg/mL), linezolid (dimethyl sulfoxide, 0.015-33 µg/mL), monensin (ethanol, 0.015-33 
µg/mL), rifampicin (dimethyl sulfoxide, 0.00023-33 µg/mL), sulfacetamide (water, 0.015-
320 µg/mL), and vancomycin (water, 0.015-33 µg/mL). Concentration ranges were 
selected based on reported MIC90 values for the antibiotics in literature. To prepare the 
plate, 5 µL of each treatment was added to the top row which contained 145 µL of MRSA 
culture. Then 50 µL of the top row was transferred, after mixing, to the next row and the 
same volume was transferred down the plate resulting in a final culture volume of 100 µL 
in all wells. The plate was incubated at 37 °C with shaking at 60 rpm for 6 hours. OD600 
readings were recorded and dose response curves were plotted in GraphPad.  
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Based on the dose response results, antibiotic concentrations that suppressed 
growth by 20-50% relative to the solvent control were selected for a follow-up study 
performed with the MRSA culture volume intended for the metabolomics experiment (10 
mL). To simplify the number of controls necessary due to the different solubilities of the 
antibiotics chosen for the experiment, every culture condition (treatments and control) 
contained a mixture of all of the solvents used to dissolve the different antibiotics (0.53% 
aqueous acetic acid (0.1 % of final solution); water (0.66% of final solution); ethanol 
(0.14% of final solution); methanol (0.08% of final solution); and dimethyl sulfoxide 
(0.33% of final solution)).  
4.6.2 Sample Preparation, Intracellular Metabolite Extraction, and NMR Spectral 
Acquisition for Pilot Experiment 
A total of 30 MRSA cultures (ATCC strain 33591) were grown over the course of 
three days (10 cultures per day for 5 treatment conditions tested in duplicate) in 7 mL of 
Difco Nutrient Broth dispensed in 25 mL tissue culture flasks at 37 °C with shaking at 60 
rpm for 6.5 hours, the amount of time it took for MRSA to reach late exponential growth. 
For each test day, media was pre-treated with the different solvents and antibiotic 
treatments (solvent control: mix of 5 solvents described in previous section; ciprofloxacin 
[final concentration 0.05 µg/mL] plus ethanol, methanol, water, and DMSO to amounts 
defined in previous section; monensin [final concentration 0.35 µg/mL] plus dilute acetic 
acid, methanol, water, and DMSO; sulfacetamide [final concentration 0.6 mg/mL] plus 
dilute acetic acid, ethanol, water, and DMSO; and vancomycin [final concentration 0.25 
µg/mL] plus dilute acetic acid, ethanol, methanol, and DMSO. The pre-treated media was 
then inoculated with MRSA to achieve a starting cell density of about 1 x 107 cells/mL. 
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After incubation, the cells were separated from the media using vacuum filtration with PES 
filters (Supor, 0.45 μm pore size, Pall Laboratory) and the cells were rinsed with chilled 
0.6% aqueous NaCl solution. The filter was transferred to a sterile 50 mL polypropylene 
tube containing cold 70% aqueous ethanol, vortexed to transfer cells from the filter to the 
solvent, and the 70% aqueous ethanol was transferred to a sterile 15 mL polypropylene 
tube containing 0.5 mm zirconia/silica beads. The cells were lysed by vortexing the 
cell/methanol/bead mixture and then centrifuged to pellet the cells and beads. After the 
supernatant was transferred to a glass scintillation vial, the cell/aqueous ethanol/bead 
mixture was rinsed three times with 70% aqueous ethanol. The resulting intracellular 
extract was dried in a speed vacuum concentrator before being subjected to liquid/liquid 
partition with a 3:1.4:1.6 mixture of chloroform, water, and methanol. The resulting 
nonpolar and polar extracts were dried in the speed vacuum concentrator and lyophilized 
prior to NMR spectral analysis. The nonpolar samples were resuspended with 150 μL of 
CDCl3 while the polar samples were dissolved in 99.8% D2O solution containing 50 mM 
phosphate buffer (pH 7.2, uncorrected) and 50 μM 3-(trimethylsilyl)propionic acid-2,2,3,3-
d4 (TMSP-d4) as an internal standard for chemical shift referencing before being 
transferred to 3 mm NMR tubes. 1H NMR spectra were acquired on a 16.4 T (700 MHz for 
1H) Bruker Advance III HD instrument with a 5mm indirect broadband cryoprobe. 
4.6.3 Metabolomic Data Analysis 
1H NMR spectral data were preprocessed in Metabolab. TMS was used to align 
spectra at 0.00 ppm and all spectra were manually phased and baseline corrected prior to 
removal of the spectral regions around TMS (-2.00 to 0.50), D2O (4.50 to 5.50), and 
unoccupied downfield region (8.51 to 14.60). All spectra were noise filtered, binned (0.005 
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ppm), and probabilistic quotient normalized. PLS toolbox version 8.1 in Matlab was used 








Natural product drug discovery continues to provide valuable leads for new medicines 
despite the shift in focus of pharmaceutical companies to combinatorial chemistry and high 
throughput screening of synthetic chemical libraries over the last few decades.[9] The 
decision to deprioritize natural product discovery programs was in part due to challenges 
presented by the limited supply of natural products as well as difficulties encountered while 
pursuing synthetic routes since many natural products are comprised of complex scaffolds. 
Additionally, there is a high rate of re-discovery of known bioactive molecules in screening 
programs.[179] Taking steps to understand the mechanisms of action (MOAs) of these 
complex molecules, as reported in chapters 1 and 4, can help boost the likelihood that 
pharmaceutical companies pursue development of drugs derived from natural products, 
especially if the MOA is found to be novel. An additional benefit to elucidating the MOA 
of a natural product is that it can help identify the drug’s pharmacophore which can in turn 
lead to a medicinal chemistry program towards development of lead molecules with 
reduced structural complexity.[180]  
Synthetic biology provides a number of solutions to existing challenges with 
natural product drug development. Knowledge of the biosynthetic gene clusters encoding 
enzymes required for assembly of these complex molecules is the first step towards a 
biological solution to natural product synthesis. More specifically, genetic engineering to 
express biosynthetic gene clusters in a scalable microbial system such as E. coli can enable 
access to complex chemical structures (including with control of stereochemistry) with 
improved yields.[181] Additionally, research on cryptic biosynthetic gene clusters has 
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provided promising routes to promoting production of novel chemical entities.[182] In the 
field of chemical ecology, induction of chemical defenses produced by cryptic biosynthetic 
gene clusters has been reported. For example, a Streptomyces sp. and Aspergillus sp. co-
isolated off Heron Island in Australia were found to be involved in chemical warfare where 
a metabolite produced by the fungus Aspergillus sp. stimulated nitric oxide production by 
the bacterium Streptomyces sp. which in turn activated a silent biosynthetic gene cluster 
that produced the antifungal natural product heronapyrrole B.[183] Identifying such 
interactions or exploring the role of a natural product in its native environment, as was 
done in chapter 2, can assist in promoting production of these unique, bioactive molecules 
from cryptic biosynthetic gene clusters.  
Advancements in the field of natural products chemistry have been greatly aided by 
improvements in structure elucidation instrumentation, construction of small molecule 
databases, and the use of informatics tools to analyze complex datasets. Advances in 
instrumentation have made it possible to identify natural products produced in very small 
natural yields and to quickly identify known compounds within complex mixtures. In 
chapter 1, microgram quantities of new and previously identified cyanobacterial natural 
products were isolated; without the sensitivity and spectral dispersion of an 800 MHz NMR 
spectrometer, deciphering the structures would not have been feasible. Chapters 1 and 3 
made use of NMR spectroscopy and LC/MS early in the isolation process to assist in 
dereplication efforts. Although this did lead to identification of known natural products, 
the novelty of the bioassays used for screening meant that even if known natural products 
were responsible for the observed bioactivity, their promise for treating a neglected disease 
with few pharmacological options provided motivation for structural characterization.  
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The future of natural products chemistry looks bright. Valuable resources to aid in the 
identification of molecules, such as the Global Natural Products Social Molecular 
Networking (GNPS) database,[184] MarinLit,[7] and the Natural Product Atlas,[185] 
continue to emerge and increase in sophistication. New approaches to data analytics, such 
as molecular networking, enable organization and hypothesis-driven exploration of large, 
complex datasets that would otherwise be overwhelming to analyze.[186] New informatics 
systems have also been developed to analyze NMR spectral data, for example, Small 
Molecule Accurate Recognition Technology (SMART).[187] This technique makes use of 
non-uniform sampling 2D NMR spectroscopy and deep Convolutional Neural Networks 
to aid in dereplication and early identification of natural products before substantial 
investment in purification efforts. Computer Assisted Structural Elucidation (CASE) 
[188,189] prevents incorrect structural assignments by computationally generating possible 
structures based on experimental NMR spectral features, further increasing efficiency of 
natural products research efforts. 
This dissertation explored three distinct topics related to the field of natural products: 
discovery of therapeutics from marine organisms, evaluation of their MOAs against 
pathogens, and identification of their defensive roles in their native environment. Chapter 
1 contributes valuable knowledge for possible treatment options for malaria through the 
discovery of nanomolar antimalarial activity in the known cyanobacterial natural product 
lyngbyabellin A (3) and through the evaluation of the MOA of the antimalarial natural 
product kakeromamide B (1). Chapter 2 provides insights about the protective role of 
peyssonnoside A (7) against a marine fungus and gives a more comprehensive 
understanding for why the red alga Peyssonnelia sp. produces this natural product in such 
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high abundance. Chapter 3 demonstrates the potential for identifying natural products with 
anthelmintic activity from marine organisms, however, further steps are still needed to 
identify the bioactive molecule(s). Currently, natural products from the bioactive fractions 
submitted to collaborators in the Aroian lab have been purified and once bioactivity results 
are returned, structure elucidation of the active natural product(s) will be completed with 
the assistance of Bhuwan Chhetri of the Kubanek lab before returning pure natural 
product(s) to the Aroian lab for evaluation of potency against infectious hookworms. 
Chapter 4 presents a viable method for exploring the MOA of a novel compound through 
the systems biology approach of metabolomics. To complete the work presented in this 
chapter, a full metabolomics experiment with cladophorol D (17) and nine antibiotics with 
known MOAs will be performed with the help of Nolan Barrett of the Kubanek lab. The 
resulting intracellular metabolite extracts will be evaluated using NMR spectroscopy and 
LC/MS analysis. Despite chapters 3 and 4 being adversely impacted by the shutdown 
caused by COVID-19, the work presented in this dissertation represents a substantial body 
of work that has positively contributed to the field of natural products. Additionally, every 










Figure A 1. HRESIMS of kakeromamide B (1), m/z [M+H]+ calculated for 
C42H59N6O7S 791.4166, found 791.4150 (∆ = 2.0 ppm); [M+Na]
+ calculated for 
C42H58N6O7SNa 813.3985, found 813.3958 (∆ = 3.3 ppm). 
 
jk191009-01 #494-526 RT: 3.92-4.17 AV: 33 NL: 1.60E8
T: FTMS + p ESI Full ms [150.00-2000.00]
































































Figure A 6. HRESIMS of ulongamide A (2), m/z [M + Na]+ calculated for 







JK170828-01 #190-253 RT: 1.50-1.99 AV: 64 NL: 5.00E8
T: FTMS + p ESI Full ms [150.00-2000.00]










































Figure A 8. COSY spectrum of ulongamide A (2) in CDCl3 (800 MHz).
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Table A 1. Comparison of 1H NMR chemical shifts of ulongamide A (2) reported 
in literature [47] (500 MHz, CDCl3) to experimental values of 2 (700 MHz, CDCl3). 
Unit 




C/H no. δH (J in Hz) δH (J in Hz) 
Amha 
1       
2 2.68, qd (6.9, 2.8) 2.69, m 0.01 
3 4.31, m 4.31, m 0 
4a 1.43, m 1.43, m 0 
4b 1.54, m 1.55, m 0.01 
5 1.43, m 1.43, m 0 
6 0.97, t (7.0) 0.97, t (7.0) 0 
7 1.22, d (6.9) 1.22, d (6.9) 0 
NH 8.95, d (10.8) 8.94, d (10.6) 0.01 
Ala-
thz-ca 
1       
2       
3 8.04, s 8.03, s 0.01 
4       
5 5.33, quint (6.6) 5.33, quint (6.6) 0 
6 1.45, d (6.6) 1.45, d (6.7) 0 
NH 8.17, d (6.6) 8.16, d (6.7) 0.01 
N-Me-
Val 
1       
2 4.50, d (10.8) 4.50, d (10.8) 0 
3 2.33, m 2.33, m 0 
4 0.59, d (7.0) 0.60, d (6.8) 0.01 
5 0.84, d (6.6) 0.85, d (6.4) 0.01 
N-CH3 2.99, s 2.99, s 0 
N-Me-
Phe 
1       
2 6.08, dd (9.4, 5.5) 6.08, dd (9.4, 5.6) 0 
3a 3.14, dd (−15.2, 5.5) 3.15, dd (15.2, 5.5) 0.01 




Table A 1 (continued) 
N-Me-
Phe 
4       
5/9 7.16, d (7.2) 7.16, d (7.5) 0 
6/8 7.29, m 7.29, t (7.5) 0 
7 7.25, m 7.24, m 0.01 
N-CH3 3.20, s 3.20, s 0 
lactic  
acid 
1       
2 5.15, q (6.6) 5.16, q (6.7) 0.01 




Figure A 9. HRESIMS of lyngbyabellin A (3), m/z [M + H]+ calculated for 
C29H41Cl2N4O7S2 691.1788, found 691.1771 (∆ = 2.5 ppm); m/z [M + Na]
+ calculated for 
C29H40Cl2N4O7S2Na 713.1608, found 713.1590 (∆ = 2.5 ppm). 
  
jk190830-01 #790-885 RT: 6.27-7.02 AV: 96 NL: 6.62E6
T: FTMS + p ESI Full ms [100.00-2000.00]
































































Figure A 11. COSY NMR spectrum of lyngbyabellin A (3) in CDCl3 (700 MHz).
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Table A 2. Comparison of 1H NMR chemical shifts of lyngbyabellin A (3) reported 
in literature [48] (500 MHz, CDCl3) to experimental values of 3 (700 MHz, CDCl3). 





   
2 
   
3 5.31, dd (10.6, 2.3) 5.30, dd (10.9, 2.3) 0.01 
4a 1.33, m 1.31, m 0.02 
4b 1.72, m 1.73, m 0.01 
5 1.60, m 1.64, m 0.04 
6a 2.00, m 1.99, p (2.4) 0.01 
6b 2.22, ddd 
(−14.2, 10.8, 5.2) 
2.22, m 0 
7 
   
8 2.05, s 2.05, s 0 
9 1.31, s 1.31, s 0 
10 1.36, s 1.35, s 0.01 
11 
   
12 
   
13 8.09, s 8.08, s 0.01 
14 
   
15 5.24, dd (9.0, 6.8) 5.25, dd (8.6, 6.6) 0.01 
15-NH 7.27, d (9.0) 7.07, d (9.0) 0.2 
16 1.97, m 1.94, q (2.6) 0.03 
17a 1.13, m 1.13, d (6.8) 0 
17b 1.50, m 1.52, m 0.02 
18 0.90, t (7.3) 0.91, t (7.4) 0.01 
19 0.75, d (6.6) 0.76, d (6.8) 0.01 
20 
   
21a 3.70, dd (−17.0, 4.3) 3.67, dd (17.1, 4.0) 0.03 
21b 4.70, dd (−17.0, 9.2) 4.73, dd (17.1, 9.2) 0.03 
21-NH 7.97, dd (9.2, 4.3) 7.87, m 0.1 
22 
   
23 
   
24 8.23, d (0.8) 8.23, d (0.6) 0 
25 
   
26 6.13, d (0.8) 6.14, d (0.6) 0.01 
27 
   
28 1.24, s 1.24, s 0 





Figure A 12. HRESIMS of 18E-lyngbyaloside C (4), m/z [M + Na]+ calculated for 







jk190911-01 #417-433 RT: 3.31-3.43 AV: 17 NL: 1.98E7
T: FTMS + p ESI Full ms [150.00-2000.00]




















































Figure A 14. COSY NMR spectrum for 18E-lyngbyaloside C (4) in CDCl3 (700 MHz). 
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Table A 3. Comparison of 1H NMR chemical shifts of 18E-lyngbyaloside C (4) 
reported in literature [49,190] (600 MHz, CDCl3) to experimental values of 4 (700 MHz, 
CDCl3). 




1       
2a 2.49, d (−12.1) 2.52, d (12.2) 0.03 
2b 2.38, d (−12.1) 2.41, d (12.2) 0.03 
3       
3-OH 4.57, brs 4.60, s 0.03 
4a 2.09, m 2.13, m 0.04 
4b 1.28, m 1.26, m 0.02 
5 4.10, m 4.12, m 0.02 
6a 1.89, m 1.92, m 0.03 
6b 1.15, m 1.19, m 0.04 
7 3.79, t (10.1) 3.81, t (10.3) 0.02 
8a 1.70, m 1.72, m 0.02 
8b 1.45, m 1.46, m 0.01 
9a 1.45, m 1.46, m 0.01 
9b 1.32, m 1.30, m 0.02 
10 1.48, m 1.48, m 0 
11 4.26, m 4.29, m 0.03 
12a 2.77, d (−15.6) 2.79, d (15.3) 0.02 
12b 1.44, dd (−15.6, 5.3) 1.44, m 0 
13       
14a 1.97, m 1.98, m 0.01 
14b 1.63, m 1.65, m 0.02 
15a 2.17, m 2.13, m 0.04 
15b 2.18, m 2.18, m 0 




Table A 3 (continued) 
17 5.99, dd (14.6, 10.6) 6.01, dd (15.2, 10.7) 0.02 
18 6.63, dd (13.9, 10.6) 6.67, dd (13.5, 10.7) 0.04 
19 6.17, d (13.9) 6.19, d (13.5) 0.02 
20 0.80, d (7.0) 0.81, d (6.7) 0.01 
21 1.50, s 1.53, s 0.03 
1′ 4.97, brs 4.99, d (1.9) 0.02 
2′ 3.46, dd (3.0, 1.0) 3.49, m 0.03 
2′-O-Me 3.49, s 3.49, s 0 
3′ 3.42, dd (9.0, 3.0) 3.44, dd (9.4, 3.3) 0.02 
3′-O-Me 3.48, s 3.48, s 0 
4′ 3.08, dd (10.0, 9.0) 3.11, t (9.4) 0.03 
4′-O-Me 3.52, s 3.54, s 0.02 
5′ 3.53, dq (10.0, 6.2) 3.56, m 0.03 




Figure A 15. HRESIMS of lyngbyaloside (5) m/z [M + Na]+ calculated for 







jk190911-02 #506-539 RT: 4.01-4.27 AV: 34 NL: 1.17E8
T: FTMS + p ESI Full ms [150.00-2000.00]


























































Figure A 17. COSY NMR spectrum for lyngbyaloside (5) in CDCl3 (700 MHz).
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Table A 4. Comparison of 1H NMR chemical shifts of lyngbyaloside (5) reported 
in literature [50] (600 MHz, CDCl3) to experimental values of 5 (700 MHz, CDCl3). 





1   
  
2 2.66, q (7.0) 2.68, q (7.0) 0.02 
3   
  
3-OH 4.79, d (2.5) 4.81, d (1.7) 0.02 
4a 2.20, dd (12.0, 4.0) 2.23, dd (12.0, 4.5) 0.03 
4b 1.13, t (12.0) 1.15, t (11.6) 0.02 
5 4.12, m 4.14, m 0.02 
6a 2.20, dd (12.0, 4.0) 2.23, dd (12.0, 4.5) 0.03 
6b 1.02, q (11.5) 1.03, q (11.1) 0.01 
7 3.73, bt (11.0) 3.73, bt (10.8) 0 
8 1.82, m 1.84, m 0.02 
9 3.87, bd (10.6) 3.89, bd (10.6) 0.02 
10a 2.13, m 2.14, m 0.01 
10b 1.98, m 1.99, m 0.01 
11 5.40, dt (10.7, 7.5) 5.43, dt (10.7, 7.7) 0.03 
12 5.37, t (10.7) 5.38, t (10.3) 0.01 
13 2.54, m 2.55, m 0.01 
14a 1.65, ddd 
(14.0, 10.0, 3.0) 
1.66, m 0.01 
14b 1.42, bdd (14.0, 11.0) 1.44, dd (15.0, 10.7) 0.02 
15 5.48, bdd (11.0, 6.6) 5.49, dd (11.1, 6.7) 0.01 
16 5.70, dd (15.3, 6.5) 5.72, dd (15.3, 6.7) 0.02 
17 6.13, dd (15.3, 10.8) 6.15, dd (15.0, 11.2) 0.02 
18 6.67, dd (13.6, 10.8) 6.68, dd (13.6, 10.9) 0.01 
19 6.36, d (13.6) 6.38, d (13.5) 0.02 
20 1.18, d (7.0) 1.20, d (7.2) 0.02 
21 0.91, d (7.0) 0.92, d (7.0) 0.01 
22 1.04, d (6.3) 1.06, d (6.3) 0.02 
1‘  5.01, d (2.0) 5.03, d (1.7) 0.02 
2‘  3.52, dd (2.7, 2.0) 3.51, dd (3.3, 1.9) 0.01 
2′-O-Me 3.48, s 3.50, s 0.02 
3‘  3.44, dd (9.3, 3.3) 3.47, dd (9.3, 3.3) 0.03 
3′-O-Me 3.47, s 3.49, s 0.02 




Table A 4 (continued) 
 
4′-O-Me 3.54, s 3.56, s 0.02 
5‘  3.57, m 3.58, m 0.01 































jk190911-04 #360-378 RT: 2.86-3.00 AV: 19 NL: 8.40E7
T: FTMS + p ESI Full ms [150.00-2000.00]

















































Figure A 20. HRESIMS of lyngbyabellin-like 2 (LYN2). 
 
jk190911-05 #385-412 RT: 3.05-3.26 AV: 28 NL: 8.46E7
T: FTMS + p ESI Full ms [150.00-2000.00]





















































Figure A 21. 1H NMR spectrum of lyngbyabellin-like 2 (LYN2) in CDCl3 (700 MHz).
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